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ABSTRACT
THE BIOCHEMISTRY OF URSOLIC ACID:
A POTENTAL THERAPEUTIC FOR NEURO-INFLAMMATION
by
Emma Jane Arsenault
University of New Hampshire
Ursolic acid (UA) is a naturally occurring triterpenoid found in a variety of plants and berries.
This molecule has potent antioxidant and anti-inflammatory properties with the potential to treat
a wide variety of conditions, including neuro-inflammatory disorders. However, the exact
mechanism of action for UA is unknown. In this thesis, the fundamental biochemistry of UA was
investigated by studying two potential targets: lipid rafts and protein phosphatases. Lipid rafts
are an important platform for a wide variety of signal transduction pathways and are a docking
point for the assembly of the pro-inflammatory NADPH oxidase 2. The impact of UA on lipid
raft formation in neuronal cells was investigated using confocal microscopy. Protein
phosphatases are also implicated in many neurological diseases; in particular, the human protein
phosphatase 2C (PP2C) is known to cause apoptotic and neurodegenerative effects. The effects
of UA on folding on RsbX, a representative protein serine phosphatase from Bacillus subtilis
which highly resembles PP2C, were investigated using circular dichroism spectroscopy. It was
found that UA does not significantly impact the folding of the protein phosphatase, but it does
alter the dynamics of lipid raft microdomains in neuronal cells. Taken together, these results
indicate an anti-inflammatory mechanism of UA involving lipid raft perturbation and provide
support for the future development of UA as an anti-neuro-inflammatory or anti-lipid raft
treatment.
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PROJECT AIMS AND HYPOTHESIS
The naturally occurring small molecule ursolic acid (UA) has demonstrated therapeutic potential
for a wide range of diseases in various research studies. It has shown anti-inflammatory,
antioxidant, and neuroprotective effects, as well as potential anticancer and antimicrobial
abilities. Despite numerous findings demonstrating the efficacy of UA to treat disease in cellular
and animal models, its exact mechanism of action remains unknown. To advance UA as a
potential drug, it is necessary to assess its fundamental biochemistry. This will help deduce what
specific neuro-inflammatory disorders UA may be useful for and develop knowledge of which
cellular pathways this molecule is impacting. In this research project, the biochemistry of UA
was studied in vitro to investigate potential mechanisms of its effects. The results of this project
have impacts on the future of therapeutics for neuro-inflammation and other diseases, as
additional knowledge on the actions of this molecule can help enable future drug development
efforts using UA. The goals of this project were accomplished in the following specific aims:

Aim 1: Investigate the effects of ursolic acid on lipid raft formation in neuronal cells. It was
hypothesized that ursolic acid would prevent or reduce the formation of lipid rafts. SH-SY5Y
neuroblastoma cells were grown on poly-lysine coated coverslips. Cells were then treated with
ursolic acid +/- tumor necrosis factor 𝛼 (TNF𝛼). Lipid rafts were visualized using Alexa Fluor
555 labeling and slides were imaged using a confocal microscope.

Aim 2: Study the impact of ursolic acid on protein folding of a serine phosphatase. It was
hypothesized that ursolic acid would disrupt the protein folding of RsbX, a bacterial serine
phosphatase used to represent the similar human protein phosphatase PP2C. RsbX was
expressed and purified in Escherichia coli cells. The thermodynamic properties and stability of

x

the native protein were assessed using circular dichroism (CD). Then, CD was used to study the
secondary structure of RsbX when incubated with ursolic acid compared to control.

xi

CHAPTER 1

INTRODUCTION

SPHINGOLIPIDS AS REGULATORS OF NEURO-INFLAMMATION AND NADPH
OXIDASE 2*

1.1. Abstract
Neuro-inflammation accompanies numerous neurological disorders and conditions where it can
be associated with a progressive neurodegenerative pathology. In a similar manner, alterations in
sphingolipid metabolism often accompany or are causative features in degenerative neurological
conditions. These include dementias, motor disorders, autoimmune conditions, inherited
metabolic disorders, viral infection, traumatic brain and spinal cord injury, psychiatric
conditions, and more. Sphingolipids are major regulators of cellular fate and function in addition
to being important structural components of membranes. Their metabolism and signaling
pathways can also be regulated by inflammatory mediators. Therefore, as certain sphingolipids
exert distinct and opposing cellular roles, alterations in their metabolism can have major
consequences. Recently, regulation of bioactive sphingolipids by neuro-inflammatory mediators
has been shown to activate a neuronal NADPH oxidase 2 (NOX2) that can provoke damaging
oxidation. Therefore, the sphingolipid-regulated neuronal NOX2 serves as a mechanistic link
between neuro-inflammation and neurodegeneration. Moreover, therapeutics directed at
sphingolipid metabolism or the sphingolipid-regulated NOX2 have the potential to alleviate
neurodegeneration arising out of neuro-inflammation.

* Arsenault, E. J., McGill, C. M., & Barth, B. M. (2021). Sphingolipids as regulators of neuroinflammation and NADPH oxidase 2. NeuroMolecular Medicine, 23, 25-46.
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1.2. Sphingolipid Biology
Sphingolipids were first discovered in the tissues of the brain in the late 1800s and were named
after the Sphinx as their function was mysterious and unknown. Our understanding of
sphingolipids has grown immensely since. Sphingolipids are key components of membranes but
also play important roles in cell death and survival, as well as in many other processes such as
inflammation (Hannun and Obeid 2018; Hirabayashi et al. 2006). Sphingolipids are composed of
a sphingoid backbone, which can be modified by phosphorylation, glycosylation, acylation, and
more. Sphingolipid metabolism can be characterized as being ceramide-centric as the ceramide is
at the nexus of metabolic pathways diverging to distinct sphingolipids (Hannun and Obeid 2018;
Barth et al. 2011; Gault et al. 2010).

1.2.1. Sphingolipid Metabolism
Ceramide, the presumptive center of sphingolipid metabolism, can be synthesized and
metabolized in a variety of ways (Figure 1.1). The de novo synthesis of ceramide begins in the
endoplasmic reticulum and is a multi-step process. This begins with the condensation of the
amino acid serine and palmitoyl-CoA, which is catalyzed by serine palmitoyl-transferase (SPT)
to yield 3-keto-dihydrosphingosine (Hannun and Obeid 2018; Barth et al. 2011). In unique cases,
occurring in certain types of neuropathies, other amino acids can be utilized by SPT to generate a
unique line of sphingolipids (Lone et al. 2019). De novo ceramide synthesis normally continues
with 3-ketodihydrosphingosine reductase (KDSR) generating dihydrosphingosine, which can
then undergo acylation to form dihydroceramide (Hannun and Obeid 2018; Barth et al. 2011)
(Figure 1.2). This acylation is catalyzed by members of the (dihydro)ceramide synthase (CERS16) enzyme family. As the name implies, these enzymes also catalyze the formation of ceramide
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from sphingosine, which is important in a distinct metabolic node from the de novo ceramide
synthesis pathway. Importantly, CERS1-6 has somewhat unique fatty acid specificity meaning
that their activities can result in the formation of distinct dihydroceramide, and ceramide, species
with different acyl chain lengths. The final step in de novo ceramide synthesis is undertaken by
dihydroceramide desaturases (DES1-2) to introduce the 4,5 trans double bond to form ceramide
(Hannun and Obeid 2018; Barth et al. 2011) (Figure 1.2).

Figure 1.1. Ceramide-centric sphingolipid metabolism. Ceramide is lies at the nexus of
various sphingolipid metabolic pathways. The generation of ceramide and its metabolites is
tightly regulated because sphingolipids are important regulators of cellular fate and function.
αGalA α-galactosidase A; ASA arylsulfatase A; C1PP ceramide-1-phosphate phosphatase;
CDases ceramidases; CERK ceramide kinase; CERS ceramide synthase; CGT ceramide
galactosyltransferase; CST cerebroside sulfotransferase; DES dihydroceramide desaturase;
DGAT2 diacylglycerol acyltransferase 2; GALC galactosylceramidase; Gb3S
globotriaosylceramide synthase; GCases glucocerebrosidases; GCS glucosylceramide synthase;
KDSR 3-ketodihydrosphingosine reductase; LacCer lactosylceramide; SMases
sphingomyelinases; SMS sphingomyelin synthases; SMSr sphingomyelin synthase-related
protein; SPHK sphingosine kinase; SPL sphingosine-1-phosphate lyase; SPP sphingosine-1phosphate phosphatase; SPT serine palmitoyl-transferase; ST3GAL5 GM3/GM4S synthase.
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From ceramide, sphingolipid metabolism can continue along seven known and distinct
metabolic nodes (Figure 1.1). In the most well-characterized pathway, ceramide can be
deacylated to form sphingosine by a series of enzymes with unique pH optima that are known as
ceramidases (CDases) (Figure 1.2). This is a prominent pathway as this activity generates the
precursor to sphingosine-1-phosphate (S1P), which is ultimately formed by the activity of the
sphingosine kinases (SPHK1-2) (Hannun and Obeid 2018; Barth et al. 2011; Maceyka et al.
2012; Gault et al. 2010; Tsai and Han 2016) (Figure 1.2). The central and classical dogma of
bioactive sphingolipids counter-opposes ceramide and S1P as either pro-death/stress or prosurvival/mitogenic mediators, respectively. There exists one recognized exit from the collective
sphingolipid pathway where S1P can be irreversibly catabolized by the S1P lyase (SPL) to form
hexadecenal and ethanolamine phosphate. Alternatively, the phosphate head group can be
removed from S1P by S1P phosphatases (SPP1-2) to regenerate sphingosine, which can then be
re-acylated to ceramide by CERS1-6 (Hannun and Obeid 2018; Barth et al. 2011; Maceyka et al.
2012; Johnson et al. 2003). Interestingly, SPHK1-2 and SPP1-2 can also regulate the
interconversion of dihydrosphingosine and dihydrosphingosine-1-phosphate. This is noteworthy
because recent studies have described unique physiological and immune-regulatory roles for
dihydrosphingosine-1-phosphate as compared with S1P (Barth et al. 2013). In a separate
metabolic node, ceramide can be phosphorylated by ceramide kinase (CERK) to form ceramide1-phosphate (C1P) (Figure 1.2), which is becoming known as a potent regulator of inflammatory
pathways (Hannun and Obeid 2018; Barth et al. 2011). As with several other metabolic nodes,
C1P can also be de-phosphorylated by a C1P phosphatase (C1PP) activity that has yet to be
conclusively characterized (Boudker and Futerman 1993; Gómez-Muñoz 2006; Shinghal et al.
1993). Interestingly, a recent study using transfected HEK293 cells reported that sphingomyelin
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phosphodiesterase acid-like 3b (SMP-DL3b) may have C1PP activity (Mitrofanova et al. 2019).
In a more recently recognized metabolic node, ceramide can be acylated at the 1-hydroxyl
position by diacylglycerol acyltransferase 2 (DGAT2) to generate the highly hydrophobic 1-Oacylceramide (Senkal et al. 2017). Presumably, this is also a reversible pathway and has been
shown to be important in the broader implication of ceramide storage in lipid droplets in cancer
and metabolic disorders (Senkal et al. 2017).

Figure 1.2. Sphingolipid chemical structures. The chemical structures of representative
species of dihydroceramide, ceramide, sphingosine, sphingosine-1-phosphate (S1P), ceramide-1phosphate (C1P), sphingomyelin, and glucosylceramide.
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One of the most well-established metabolic nodes in ceramide-centric sphingolipid
metabolism is the sphingomyelin pathway (Figure 1.1). In this metabolic node, ceramide is used
as a precursor to generate sphingomyelin by the sphingomyelin synthases (SMS1-2) (Figure 1.2).
Briefly, a more recently described ceramide metabolic outlet similarly uses SMS2, as well as the
SMS-related protein (SMSr) to generate ceramide phosphoethanolamine (Bickert et al. 2015).
The respective reverse activity has been observed but is not yet characterized. In contrast, the regeneration of ceramide from sphingomyelin is one of the best characterized activities.
Sphingomyelin hydrolysis to ceramide is carried out through the activities of the
sphingomyelinases (SMases) with unique pH optima (Shanbhogue and Hannun 2020; Hannun
and Obeid 2018; Barth et al. 2011; Norman et al. 2010). Mostly notably, this involves the acid
sphingomyelinase (aSMase) as well as a variety of neutral sphingomyelinases (nSMases) that
also may have dependency on magnesium (Mg2+) or manganese (Mn2+) ions (Shanbhogue and
Hannun 2020). In neuronal cells, the pro-inflammatory cytokine tumor necrosis factor α (TNFα)
was shown to activate the Mg2+-dependent nSMase2 (Barth et al. 2012a). Importantly, the
ceramide–sphingomyelin cycle can be intimately tied to the diacylglycerol-phosphatidylcholine
cycle where the phosphocholine head group is interchanged between the ceramide and
diacylglycerol lipid backbones. Additionally, the activity of nSMase has been associated with a
variety of inflammatory-triggered signaling pathways to facilitate the rapid generation of
ceramide (Hannun and Obeid 2018; Barth et al. 2011, 2012a). Likewise, aSMase can participate
in rapid ceramide generation, but when this activity is confined in the lysosome, this ceramide
can be rapidly and further catabolized by acid CDase to yield sphingosine (Hannun and Obeid
2018; Barth et al. 2011; Kitatani et al. 2008). Importantly, this sphingosine can leave the
lysosome and traffic to membranes where it can become a substrate for CERS1-6 to regenerate
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ceramide. This “ceramide to sphingosine and back to ceramide” route may seem circuitous, but it
is enabled by the movement of sphingolipids between different subcellular locations. This is also
known collectively as the salvage pathway of ceramide generation and is also engaged when
glycosphingolipids are catabolized through the acidic lysosomal pathway.
Finally, two of the most substantial metabolic nodes from ceramide collectively mediate
glycosphingolipid metabolism through the generation of either glucosylceramide or
galactosylceramide (Figure 1.1). Glucosylceramide synthase (GCS) catalyzes the generation of
glucosylceramide from ceramide at the Golgi (Figure 1.2), whereas ceramide
galactosyltransferase (CGT) is responsible for the generation of galactosylceramide from
ceramide (Gault et al. 2010). Glucosylceramide serves as a precursor to lactosylceramide, which
is then used as a building block for a wide variety of glycosphingolipids including many of the
gangliosides and the globosides (D’angelo et al. 2013). Galactosylceramide can also serve as a
building block to many other glycosphingolipids including the sulfatides, GM4 ganglioside, and
digalactosylceramide (Farrell and McKhann 1971; Uemura et al. 2014; Wang et al. 2020a, b).
These metabolic pathways that generate glycosphingolipids also have characterized reverse
activities that can regenerate many of the precursors. As with sphingomyelin, glucosylceramide
and galactosylceramide can be degraded to yield ceramide through the activities of the
glucocerebrosidases (GCases) and galactosylceramidase (GALC), respectively. More so, many
of these catabolic enzymes have unique pH optima with those that utilize the acidic lysosomal
axis contributing to the ceramide salvage synthesis pathway.
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1.3. Sphingolipid Signaling
Sphingolipids play diverse roles in cell signaling, and each sphingolipid can exert unique
functions within cells. Ceramide and S1P are classically viewed as having opposing functions
with ceramide acting as a pro-apoptotic and cellular stress regulator (Hannun and Obeid 2018;
Barth et al. 2011), while S1P exerts a mitogenic and pro-survival role (Maceyka et al. 2012; Tsai
and Han 2016). However, there are exceptions to this central dogma. Additional sphingolipids
have been shown to play roles in signaling pathways associated with neuro-inflammation and
neurodegeneration.

1.3.1 Ceramide
Ceramide typically functions as a pro-apoptotic sphingolipid, contributing to the termination of
growth and initiation of apoptosis (Barth et al. 2011). Due to this profound role and its position
at the center of sphingolipid metabolism, ceramide signaling is relevant in many disease
pathologies, including neuro-inflammatory conditions (De Wit et al. 2019). Ceramide is widely
appreciated to impact pro-apoptotic and cellular stress signaling pathways (Hannun and Obeid
2018). Ceramide can promote signaling within lipid microdomains that it enriches. It is
important to consider that there are many different subspecies of ceramide, each defined by the
length and degree of saturation of their acyl chains (Barth et al. 2011; Hannun and Obeid 2018).
Therefore, different ceramide species are now appreciated to have sometimes differing biological
effects due to the biophysics of their membrane interactions. In a classical example, ceramide
serves to form specific types of lipid microdomains to facilitate and stimulate the activity of
signaling mediators such as protein kinase C ζ (PKCζ), which can deactivate the pro-survival and
mitogenic Akt (Fox et al. 2007). Moreover, our group has demonstrated the ability of ceramide
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to cause NOX activation, defined in part by assembly of multiple subunits at the membrane,
which then leads to the production of reactive oxygen species (ROS) (Barth et al. 2010). In
summary, ceramide signaling is typically pro-apoptotic, although there are a few cases where
ceramides of different chain length can exert an opposing effect.

1.3.2. S1P
In addition to playing a well-recognized role as a mitogenic and pro-survival sphingolipid, S1P is
a potent regulator of immune responses where it plays a prominent role in the central nervous
system (CNS) (Hannun and Obeid 2018; Maceyka et al. 2012; Tsai and Han 2016). The classical
S1P signaling pathway has been well defined where it is known to bind to five unique G-protein
coupled receptors (GPCRs) called S1P receptors (S1PR1-5) (Czubowicz et al. 2019). The five
S1PRs can exert unique roles in the regulation of cell processes related to development and
immune response. As with other GPCRs, S1PRs can signal in different manners depending on
the coupling of different G-proteins. All S1PRs have been shown to signal through Gαi, and all
but S1PR1 can signal through Gα12/13; however, S1PR2 and S1PR3 may also signal though
Gαq (Maceyka et al. 2012; Czubowicz et al. 2019). S1PR1 signaling has been shown to play a
prominent role in the development of inflammatory responses with S1PR1 activation leading to
the activation of T cells and egress of both B and T cells (Maceyka et al. 2012; Tsai and Han
2016).
However, S1P signaling can also diverge from this classical dogma. It has been shown
that the actions of S1P can differ based on which enzyme phosphorylated it (Maceyka et al.
2005), which is likely due to their subcellular localization and specific S1P effects at those
locations. SPHK1 is a cytosolic enzyme that can translocate to membranes in response to
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stimulation. Its translocation to the plasma membrane is best characterized and associated with
its pro-mitogenic and pro-survival effects (Maceyka et al. 2005; Siow et al. 2010, 2011).
However, SPHK1 has also been shown to associate to other membranes including the
endoplasmic reticulum (Maceyka et al. 2005; Siow et al. 2010, 2011), mitochondria (Kim and
Sieburth 2018), and endocytic vesicles (Young et al. 2016). Its association with the mitochondria
has been linked to the mitochondria unfolded protein response (Kim and Sieburth 2018), whereas
its association with endocytic vesicles is associated with endosomal membrane trafficking and
fusion (Young et al. 2016). By comparison, SPHK2 localizes to the cytoplasm (Dominguez et al.
2018; Neubauer et al. 2019), plasma membrane (Neubauer et al. 2019), endoplasmic reticulum
(Maceyka et al. 2005), as well as the mitochondria (Sivasubramanian et al. 2015), and has also
been shown to associate with cytoplasmic motor complexes as it moves away from the plasma
membrane (Neubauer et al. 2019). Interestingly, SPHK2 has also been observed to localize in the
nucleus (Ding et al. 2007; Dominguez et al. 2018). In the nucleus, SPHK2 promotes acetylation
of histones as S1P produced by SPHK2 specifically inhibits histone deacetylases 1 and 2 (Hait et
al. 2009). This highlights an epigenetic role for S1P in the nucleus. As neurons are terminally
differentiated, the promotion of differentiation and re-entry into the cell cycle in these cells can
lead to apoptosis. In SPL-deficient neurons, S1P formed by SPHK2 promoted apoptosis, while
the same amount of S1P generated by SPHK1 was non-cytotoxic (Hagen et al. 2009). This is
likely due to the difference in signaling between nuclear S1P and S1P signaling through its
membrane GPCRs. Plasma S1P has also been shown to bind to apolipoprotein M (ApoM) to
activate a signaling cascade that prevents neuro-inflammation and differentiation of bone
marrow lymphocyte progenitors (Blaho et al. 2015). Intriguingly, although S1P has been
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classically viewed as pro-survival, it may exert pro-apoptotic effects depending on its cellular
and subcellular distribution.

1.3.3. C1P
C1P has various functions in inflammation. As a pro-inflammatory mediator, C1P has
demonstrated the ability to promote the generation of arachidonic acid, a pro-inflammatory
eicosanoid precursor, by directly activating cytosolic phospholipase A 2 (cPLA2) (Pettus et al.
2004). Other conflicting studies have demonstrated that knockout of CERK in a mouse model
led to lower level of certain pro-inflammatory cytokines while preventing insulin resistance,
suggesting that C1P may play unique roles in the generation and release of pro-inflammatory
mediators from different cell types (Mitsutake et al. 2012). Another study similarly showed that
C1P could mitigate pro-inflammatory mediators in rat primary microglia (Jung et al. 2013).
Similarly, C1P has been shown to inhibit the metalloprotease responsible for producing the
active form of TNFα (Lamour et al. 2011). However, in neuroblastoma cells, C1P generation
was shown to mediate pro-inflammatory processes including oxidative and eicosanoid pathways
(Barth et al. 2012b). Overall, the conflicting roles for C1P may be ascribed to specific bioactive
roles for the lipid that are analogous to other phospholipids. Therefore, the diversity of effects
may be more of a result of the specific cellular pathways engaged by this bioactive sphingolipid.

1.3.4. Sphingomyelin
Sphingomyelin is an important component of sphingolipid metabolism and a prominent
component of membranes that has been associated with the formation of lipid rafts (Li et al.
2007). Sphingomyelin is generated by SMS activity, which converts ceramide into
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sphingomyelin. Activation of SMS has been correlated with the production of the second
messenger diacylglycerol (Villani et al. 2008). Moreover, and of profound importance to the
rapid effects of pro-inflammatory mediators in the CNS, the breakdown of sphingomyelin into
ceramide is regulated by SMases (Barth et al. 2012a).

1.3.5. Ceramide Phosphoethanolamine
Ceramide phosphoethanolamine synthesis from ceramide can be catalyzed by SMS2 and SMSr
(Bickert et al. 2015). SMSr is the dominant synthesizer of ceramide phosphoethanolamine in the
brain, and deactivation of SMSr results in a major reduction in brain short-chain ceramide
phosphoethanolamine species in vivo (Bickert et al. 2015). The loss of SMSr can trigger
apoptosis via ceramide accumulation in the endoplasmic reticulum (Vacaru et al. 2009; Tafesse
et al. 2014). Interestingly, SMSr can be cleaved by caspase-6 during apoptosis, connecting its
regulation to the neuro-inflammatory conditions of Alzheimer’s disease and Huntington’s
disease (Cabukusta et al. 2017).

1.3.6. Glucosylceramide and Galactosylceramide
Glucosylceramide is a glycosphingolipid formed due to the activity of GCS (Gault et al. 2010).
As glucosylceramide formation requires the loss of ceramide, a pro-survival and proliferative
role for glucosylceramide has been suggested (Jennemann et al. 2005; Barth et al. 2010).
Importantly, glucosylceramide serves as the building block to a wide variety of
glycosphingolipids, notably the gangliosides and globosides, which can exert a range of distinct
effects in the CNS. Glucosylceramide is also necessary for proper brain development and mice
with GCS deficiency in neural cells die prematurely with severe defects in axons and their
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myelin sheaths (Jennemann et al. 2005). Conversely, glucosylceramide has also been shown to
contribute to neuronal death by promoting the formation of toxic α-synuclein in Parkinson’s
disease and triggering damaging neuro-inflammation in a mouse model of Gaucher’s disease
(Zunke et al. 2018; Farfel-Becker et al. 2014).
Galactosylceramide, the glycosphingolipid precursor to sulfatides, may have an antiinflammatory role in the brain. Lipopolysaccharide (LPS)-stimulated TNFα production by
microglia was blocked by in vitro treatment with α-galactosylceramide analogs (Jeong et al.
2014). Galactosylceramide is also a crucial component of myelin (Jana and Pahan 2010) and
may negatively regulate oligodendrocyte differentiation; both in vitro and in vivo, knockout of
CGT resulted in elevated amounts of terminally differentiated oligodendrocytes (Bansal et al.
1999). Digalactosylceramide is formed by the action of globotriaosylceramide synthase (Gb3S)
on galactosylceramide. Buildup of lysosomal digalactosylceramide is a factor in Fabry disease
progression, as it is one of the substrates of α-galactosidase A (αGalA), the enzyme deficient in
Fabry disease (Germain 2010).

1.3.7. Sulfatide and Gangliosides
Sulfatides are formed by the addition of a sulfate group to galactosylceramide (Farrell and
McKhann 1971). In poly-unsaturated fatty acid-deficient mice, arylsufatase A and
galactosylceramide were observed to be elevated, leading to a breakdown of sulfatides and
activation of autophagy via Erk/mTOR in the brain (Wang et al. 2020a, b). Research has also
suggested a pro-inflammatory role for sulfatide signaling. In human monocytes, addition of
exogenous sulfatides correlated with an increase in the release of various pro-inflammatory
cytokines (Constantin et al. 1994). Additionally, in primary microglia, it was demonstrated that
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sulfatides had the ability to induce phosphorylation of p38, Erk, and Jnk and to activate the NFκB pathway (Jeon et al. 2008). Due to this pro-inflammatory role, sulfatides have been
implicated in many neurological conditions and disorders with neuro-inflammatory components
(Cheng et al. 2013; Seyfried et al. 2018; Ilyas et al. 2003; Eichler and Van Haren 2007;
Annunziata et al. 2007).
Gangliosides are commonly generated by the activity of glucosyltransferases on
lactosylceramide and are characterized by the presence of at least one sialic acid residue (Kolter
et al. 2002). Gangliosides have been implicated in regulation of neuro-inflammation (Furukawa
et al. 2017). Specifically, gangliosides have been demonstrated to initiate pro-inflammatory
signaling by activating the Jak-STAT signaling pathway in primary microglia, which results in
their activation (Kim et al. 2002). Gangliosides accumulate and trigger neuro-inflammation in
the lysosomal storage disorders Niemann-Pick disease (Lloyd-Evans et al. 2008) and Tay-Sachs
disease (Myerowitz 1997).

1.4. Sphingolipid‐Mediated NADPH Oxidase 2 (NOX2) in Neuro‐Inflammation
There are seven recognized NOX enzymes (NOX1-5 and DUOX1-2, for dual oxidase). The
prototypical phagocytic NOX is NOX2 and is a complex consisting of two membrane subunits
gp91phox (also sometimes referred to as NOX2) and p22phox, and three cytosolic subunits
p47phox, p67phox, in addition to the Rac GTPase (Bedard and Krause 2007). Most NOX
enzymes generate superoxide as the primary form of ROS through an electron transport chain in
which two single electrons are transferred to two oxygen molecules in NADPH, resulting in the
formation of two superoxide ions and NADP+ (Leto et al. 2009). Oxidative stress via increased
activation of NOX2 is a factor in many disease states, including neuro-inflammatory conditions
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such as Alzheimer’s disease (Choi et al. 2012), Parkinson’s disease (Wang et al. 2015), and viral
infections with CNS complications (Jana and Pahan 2004). Pro-inflammatory cytokine-induced
NOX2 activation in neuronal cells has been shown to be mediated by the sphingolipids ceramide
and C1P (Barth et al. 2009, 2010, 2012a, b). Similarly, ceramide has been shown to regulate
NOX enzymes, including NOX2, in several other cell types and tissues (Jin et al. 2011).
Interestingly, recent evidence indicates that aSMase-generated ceramide can regulate NOX4 in
aortic endothelial cells (Li et al. 2018), whereas SMPDL3b-generated ceramide can regulate
NOX1 in glomerular endothelial cells (Abou Daher et al. 2020). The later observation contrasts
with the regulation of NOX2 due to the C1P-depleting activity of SMPDL3b (Abou Daher et al.
2020; Mitrofanova et al. 2019). In another study, an agonist of S1PR2 was shown to alleviate
platinum-based chemotherapeutic ototoxicity in cochlear neurons by decreasing oxidative stress
(Herr et al. 2016; Wang et al. 2020a, b). NOX3 was speculated as the source of oxidative stress
given its cochlear distribution, but was not studied using any pharmacological or molecular
approach. However, this is interesting because it suggests that pro-survival S1P signaling may
counter-oppose neuronal oxidative pathways, which may include those mediated by NOX2.
Overall, there is strong support linking neuro-inflammation to neurodegeneration through
ceramide and C1P mediation of NOX2 and its subsequent oxidative impacts to neuronal heath
and function.
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Figure 1.3. Sphingolipid-mediated NADPH oxidase pathway 2 (NOX2). Pro-inflammatory
mediators can trigger both neutral sphingomyelinase 2 (nSMase2) and ceramide kinase (CERK)
to generate ceramide and ceramide-1-phosphate (C1P), respectively. These bioactive lipids
stimulate the assembly and activation of NADPH oxidase 2 (NOX2), which generates
superoxide (O2-). Various proteins and enzymes can subsequently be subject to oxidation
including actin and sphingosine kinase 1 (SPHK1). Oxidation of actin in neurons impedes actin
dynamics and is detrimental to neuronal health and function. Oxidation of SPHK1 impairs
sphingosine-1-phosphate (S1P) generation and favors ceramide-mediated death (Barth et al.
2009, 2012a, b)

1.4.1. Neuro‐Inflammation and Neurological Disorders
Neuro-inflammation can have damaging consequences, such as demyelination and damage to
axons, and can contribute to the development of many neurological disorders. In fact, neuroinflammation is a factor in many sphingolipidoses (Settembre et al. 2007; Kikumoto et al. 2010;
Vitner et al. 2012; Schuchman and Desnick 2017), motor function disorders (Imarisio 2008;
White et al. 2018), dementias (Jazvinšćak Jembrek et al. 2015; De Wit et al. 2019), viral
infections (Persidsky et al. 1997; Diop et al. 2018; Wang et al. 2018), and more. These neuroinflammatory disorders result in damaging and difficult symptoms that often lead to death, and
there are little treatment options available to stop these diseases from progressing. Therefore,
investigations of the pathological mechanisms associated with neuro-inflammation and
neurodegeneration ultimately aims to uncover pathways that can be interrogated for novel drug
discovery. Recently, research has highlighted an impactful role for sphingolipids in the
modulation of neuro-inflammation (Constantin et al. 1994; Gill and Windebank 2000; Pettus et
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al. 2004; Fox et al. 2007; Maceyka et al. 2012; Tsai and Han 2016). Therefore, sphingolipidbased therapeutics may hold promise for the treatment of neurological disorders that are enabled
by neuro-inflammation.

1.4.2. Inflammatory Stimulation of Neuronal NOX2
NOX2 activation is mediated by sphingolipids and pro-inflammatory cytokine TNFα. NOX2
assembly and activation were demonstrated by movement of the p67phox cytosolic NOX subunit
to the membrane following TNFα administration of cortical neurons (Barth et al. 2009, 2012a).
The pro-inflammatory cytokine TNFα was also shown to activate both nSMase2 activity, which
hydrolyzes sphingomyelin into ceramide (Gustafson et al. 2007), and CERK activity, which
phosphorylates ceramide to C1P (Figure 1.3) (Barth et al. 2012b). Furthermore, these
sphingolipids were both shown to activate NOX2 in neuronal cells (Barth et al. 2012a, b). It is
likely that ceramide causes lipid raft organization to promote NOX2 assembly (Gustafson et al.
2012), while C1P promotes the actual recruitment of cytosolic subunits to the membrane
complex via charge-based lipid–protein interactions (Barth et al. 2012b). The activation of
NOX2 by C1P may also occur indirectly, where C1P activates cPLA 2 to promote the generation
of arachidonic acid (Pettus et al. 2004). Arachidonic acid has been recognized to activate NOX2
enzymes (Barth et al. 2009). NOX2 activation by ceramide may also occur through PKCζ, as
ceramide has been shown to stimulate the activation of PKCζ (Fox et al. 2007). PKCζ may then
mediate NOX2 assembly by phosphorylating the p47 phox cytosolic subunit, which enhances its
membrane translocation and association with gp91phox (Frey et al. 2002). Interestingly,
glucosylceramide was shown to block NOX2 assembly and activation thereby contrasting the
effects of ceramide highlighting the importance of sphingolipid metabolism to NOX2 regulation
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(Barth et al. 2010). Additional research is still needed to develop a more complete understanding
of the mechanism by which ceramide and its metabolites regulate NOX2 activation.
There is additional evidence that NOX enzymes can play roles in the development of neuroinflammation. Leukocyte recruitment in response to LPS is reduced significantly in mouse brains
with a deletion of the p47phox cytosolic subunit of NOX2 (Choi et al. 2012). Additionally,
inhibition of NOX2 in an LPS-injected Parkinson’s disease mouse model was shown to lead to a
decrease in chronic neuro-inflammation and prevented neurodegeneration (Wang et al. 2015).
Altogether, research indicates that NOX2 is activated by sphingolipids whose accumulation is
promoted by pro-inflammatory cytokines.

1.4.3. Degenerative Consequence of Neuronal NOX Activation
ROS produced by NOX has been shown to cause significant degeneration to neural cells through
damage associated with oxidative stress. In neuronal cells, ROS produced by NOX has been
shown to cause oxidative damage to actin in a manner that impairs dynamic actin filament
dynamics (Figure 1.3) (Barth et al. 2009). In addition, activation of NOX by the proinflammatory cytokine TNFα and subsequent nSMase-generated ceramide was shown to causes
oxidative damage to SPHK1 in primary cortical neurons (Figure 1.3) (Barth et al. 2012a). The
consequence of this oxidation of SPHK1 decreases pro-survival S1P and leads to a shift of
sphingolipid metabolism towards ceramide and resulting impediment of neurite outgrowth and
disruption of growth cone advance (Barth et al. 2012a). NOX-derived ROS have also been
observed to enhance the transcription of α-synuclein in Parkinson’s disease leading to
accelerated neurodegeneration (Cristóvão et al. 2012). Likewise, the consequences of neuronal
NOX-mediated oxidative damage were demonstrated using NOX4 knockout mice, which were
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protected from ischemic stroke-mediated neurodegeneration (Kleinschnitz et al. 2010).
Collectively, these studies demonstrate that neuronal NOX activation can have dramatic
degenerative consequences. Therefore, targeting neuronal NOX activity or its regulators, such as
nSMase-generated ceramide production, may be able to exert a neuroprotective effect.

1.5. Sphingolipids in Neurodegenerative Disorders
1.5.1. Alzheimer’s Disease
Alzheimer’s disease is one of the most common forms of dementia and is characterized by
abnormally processed amyloid beta (Aβ) proteins and the assembly of tau proteins into
neurofibrillary tangles (Czubowicz et al. 2019). Chronic neuro-inflammation is also a hallmark
of this disease, and the accumulation of ceramide has been described in patients with
Alzheimer’s disease (Jazvinšćak Jembrek et al. 2015; De Wit et al. 2019). Studies have
demonstrated links between ceramide and the development of neuro-inflammation due to an
accumulation of Aβ. Excess ceramides have been shown to be linked to an increase in the
amount of Aβ by stabilizing β-secretase, which is required to process the Aβ precursor protein
(AβPP) (Jazvinšćak Jembrek et al. 2015; Czubowicz et al. 2019). AβPP processing to either
Aβ40 or Aβ42 has been shown to decrease cholesterol and sphingomyelin levels, with Aβ42
reported to directly activate nSMase2 (Grimm et al. 2005). In addition, Aβ has been shown to
trigger the release of pro-inflammatory cytokines and mediators through engagement of the Tolllike receptor 2 signaling pathway (Jana et al. 2008). Importantly, the pro-inflammatory mediator
TNFα has also been shown to activate nSMase2 to generate ceramide and promote NOX2
activation (Barth et al. 2012a; Gustafson et al. 2007). Not surprisingly, the regulatory subunit of
NOX2 was also observed to be upregulated in activated microglia of Alzheimer’s disease
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patients (Choi et al. 2012). Conversely, deactivation of nSMase2 in the 5XFAD mouse model
was shown to result in lower levels of long-chain C18:0, C18:1, and C24:1 ceramides and was
associated with memory improvement (Dinkins et al. 2016). Altogether, this suggests that
nSMase2 and the generation of ceramide plays a prominent role in the pathogenesis of
Alzheimer’s disease.
Interestingly, S1P has also been ascribed a potentially conflicting role in the processing
of AβPP and subsequent accumulation of Aβ. Notably, an accumulation of full-length AβPP was
observed in cells deficient in SPL, the enzyme that irreversibly breaks down S1P, alongside an
anticipated excess of S1P (Karaca et al. 2014). However, it is important to note that while S1P is
anticipated to increase in SPL-deficient cells, there may also be increases in other sphingolipids
that can serve as precursors to S1P generation including ceramide and its other metabolites. In
another intriguing and potentially conflicting study, deletion of the gene encoding for SPHK2
was shown to result in a significant decrease in Aβ production in vivo (Lei et al. 2019).
However, while this may also suggest a link between S1P and Aβ production, it is important to
note that demyelination and declines in cognitive status were also observed in the SPHK2deficient model (Lei et al. 2019). Overall, this may indicate that S1P can play a distinct role in
the processing of AβPP. In support of this concept, it has been shown that S1P can bind to and
increase the activity of the β-secretase, BACE1, causing a rise in the levels of secreted Aβ
(Takesugi et al. 2011; Karaca et al. 2014). However, there are still questions about potential roles
for dihydrosphingosine-1-phosphate in Alzheimer’s disease, which is another SPHK2-generated
sphingolipid. Additionally, there are also questions related to changes in sphingolipid metabolic
flux and the relation to Alzheimer’s disease in these mouse models with manipulations of the
classical S1P pathway.
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Curiously, unprocessed AβPP has also been shown to have age-related effects on
sphingolipid metabolism. CERS enzymes were observed to be increased in APP+ mice at 3
months of age, but as the mice aged over the first year the expression of these enzymes decreased
(Jęśko et al. 2020). Simultaneously, a reduction in SMS enzymes also occurred with age (Jęśko
et al. 2020). This may suggest that de novo ceramide generation as well as sphingomyelin
generation may diminish as Alzheimer’s disease progresses. This might suggest further roles for
other ceramide metabolites, such as glycosphingolipids, in the progression of Alzheimer’s
disease. In one study, the ratio of hydroxylated to non-hydroxylated sulfatides in the
cerebrospinal fluid was observed to be increased in patients with Alzheimer’s disease, whereas
total cerebrospinal fluid sulfatides was unchanged (Blomqvist et al. 2017). In another study,
postmortem analysis of brains with preclinical Alzheimer’s disease revealed reduced levels of
sulfatides possibly suggestive that this is an early occurrence in the development of Alzheimer’s
disease (Cheng et al. 2013). Altogether, these studies highlight the complexity of changes to
sphingolipid metabolism that occurs during Alzheimer’s disease. Overall, pathways mediated by
sphingolipids, such as NOX2, may serve as a common mechanism by which dysfunctional
sphingolipid metabolism can contribute to the progressive degenerative state and cognitive
decline associated with Alzheimer’s disease.

1.5.2. Frontotemporal Lobar Dementia
Frontotemporal Lobar Dementia (FTLD), also known as Pick’s disease, is one of the most
common dementias and is characterized by the formation of FTLD-tau also known as Pick
bodies (Bang et al. 2015). Neuro-inflammation has also been shown to be a major factor in the
progression of FTLD (Bright et al. 2019). Research has demonstrated a role for the accumulation
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of ceramide in the development of this inflammation. Postmortem brain samples of FTLD
patients had elevated levels of ceramide in astrocytes, which correlated with increased neuroinflammation. This was found to be mediated by an increase in Cers5 expression but not aSMase
activity, leading to the generation of mostly C16 ceramide (De Wit et al. 2019). Therefore,
prevention or reduction of excess ceramide production may be an effective strategy to treat
FTLD.

1.5.3. Parkinson’s Disease
Parkinson’s disease is a neurodegenerative disorder attributed to an increase in α-synuclein,
which can trigger neuro-inflammation through an upregulation of pro-inflammatory cytokines
(White et al. 2018). Intriguingly, patient data studies have discovered that a small percentage of
individuals with Parkinson’s disease have a mutation in the Gba gene, which encodes for one of
the GCases (Neumann et al. 2009). This disruption in GCase is exacerbated by α-synuclein,
which can disrupt the trafficking of GCase from the endoplasmic reticulum. Ultimately, this
results in a lack of mature GCase (Wong and Krainc 2016). Additionally, it was shown that
raising the amount of lysosomal glucosylceramide to 75% above basal levels increased αsynuclein formation in vitro (Wong and Krainc 2016). Other studies have also shown that
glycosphingolipids, such as glucosylceramide, can promote the conversion of α-synuclein into a
neurotoxic form in a process that is reversible by inhibiting GCS (Zunke et al. 2018). Research
has also suggested that a causal relationship exists between glucosylceramide accumulation and
the specific development of neuro-inflammation in Parkinson’s disease. In a Gba knockout
mouse, elevated glucosylceramide levels were observed in accompaniment with neuroinflammation whereas there were no significant changes in other sphingolipids (Farfel-Becker et
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al. 2014). In addition, a possible role for NOX2 in Parkinson’s disease has been established.
Inhibition of NOX2 in Parkinson’s disease models has been shown to reduce the activation of
microglia, NF-κB signaling, and oxidative stress while ameliorating learning and memory
problems (Hou et al. 2019). More so, studies have shown that inhibiting NOX2 in Parkinson’s
disease models can reduce chronic neuro-inflammation and can prevent α-synuclein formation
and accumulation (Wang et al. 2015; Cristóvão et al. 2012).

1.5.4. Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder of the CNS
that causes weakness and eventual paralysis. Neuro-inflammation is a common symptom of ALS
with patients demonstrating elevated levels of pro-inflammatory chemokines (Kuhle et al. 2009).
An overall dysregulation of sphingolipid metabolism is also seen in ALS. This includes
reductions in glucosylceramide, galactosylceramide, and lactosylceramide in the spinal cord of
ALS mouse models (Henriques et al. 2018). In another study, the levels of ceramide,
sphingomyelin, cerebroside, galactosylceramide, glucosylceramide, globotriaosylceramide, and
GM1 and GM3 gangliosides were increased in the cervical spinal cord of ALS patients, as well
as in an ALS mouse model (Dodge et al. 2015). In another study using ALS patients and an ALS
mouse model, increases in ceramide and sphingomyelin were observed along with the onset of
oxidative stress prior to the development of clinical symptoms (Cutler et al. 2002). Collectively,
these studies demonstrate that sphingolipid metabolism is substantially altered in ALS and that
there may be links to oxidative stress that are associated with the degenerative nature of this
disease.
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The oxidative stress that is observed in ALS may be due to NOX2 activity, which can be
mediated by sphingolipids (Barth et al. 2009, 2012a, b). NOX2 activity has been shown to be
upregulated in the spinal cord of ALS patients as well as in an ALS mouse model. Knockout of
gp91phox (Cybb) in these mice caused an elongated lifespan, a reduction in neurodegeneration,
and delayed the onset of paralysis in this ALS mouse model (Wu et al. 2006). Combined with
other studies that demonstrate that ceramide levels are increased in ALS (Dodge et al. 2015), as
well as studies linking ceramide to NOX2 activation (Barth et al. 2012a, 2012b), it is likely that
the pathogenesis of ALS is mediated through the ceramide-NOX2 pathway.

1.5.5. Huntington’s Disease
Huntington’s disease is an autosomal dominant inherited disorder with a mutation in the gene
encoding for the huntingtin (HTT) protein. This results in the accumulation of misfolded and
toxic HTT. Symptoms typically include neurodegeneration, cognitive decline, changes in
behavior, and the loss of motor skills (Imarisio 2008). Research has demonstrated a dysfunction
in sphingolipid metabolism in Huntington’s disease. For instance, enzymes involved in the de
novo synthesis of sphingolipids were found to be dysregulated. Specifically, Cers1 was found to
be downregulated in addition to a gene encoding for a subunit of SPT (Sptlc1). Collectively, this
was observed to lead to a reduction in dihydroceramide, dihydrosphingosine-1-phosphate, and
dihydrosphingosine in late Huntington’s disease mouse brain tissues. In contrast, Cers1 was
reduced but Sptlc1 was upregulated in brain samples from early Huntington’s disease mice (Di
Pardo et al. 2017b). Collectively, this suggests an overall disturbance in de novo ceramide
synthesis that is aggravated with age in Huntington’s disease. Additionally, expression of Spl1
was found to be increased and the expression of Sphk1 was decreased in both murine
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Huntington’s disease models and postmortem Huntington’s disease human brain samples,
leading to a large reduction in S1P (Di Pardo et al. 2017a). Therefore, a stimulation of the prosurvival S1P signaling pathway may help to alleviate Huntington’s disease. Indeed, an S1PR5
agonist (A-971432) given to Huntington’s disease mouse models before the onset of symptoms
prevented loss of brain weight and alterations in the blood–brain barrier while preserving the
blood–brain barrier and delaying motor issues (Di Pardo et al. 2018). Ganglioside metabolism
has also been shown to be altered in Huntington’s disease. Levels of GM1 ganglioside were
observed to be lowered in Huntington’s disease patient samples, as well as in both cellular and in
vivo models (Maglione et al. 2010). Restoration of normal GM1 ganglioside levels may also be a
potential treatment for Huntington’s disease. In vitro treatment of Huntington’s disease cells with
GM1 ganglioside caused Akt-mediated phosphorylation of mutant HTT, which lowered its
capacity to induce cell death (Maglione et al. 2010). In addition, intraventricular injection of
GM1 ganglioside reduced the levels of mutant HTT and ameliorated symptoms of Huntington’s
disease in mice (Alpaugh et al. 2017).

1.5.6. Multiple Sclerosis and Autoimmune Encephalitis
Multiple Sclerosis (MS) is characterized by autoimmune activation of T cells, which trigger
chronic inflammation and causes demyelination and damage to axons (Weiner 2004; Brück
2005). Oligodendrocytes myelinate the neurons of the CNS. Therefore, loss of mature
oligodendrocytes can be a factor in the progression of MS. The differentiation of
oligodendrocytes has been characterized as being controlled by glycosphingolipids. Differential
expression of glycosphingolipids at specific points in the maturation cycle is responsible for the
progression of oligodendrocytes maturation (Jackman et al. 2009). Ultimately, terminal
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differentiation of oligodendrocytes is primarily mediated by sulfatide (Bansal et al. 1999).
Glycosphingolipids, especially galactosylceramide, are also an important component of myelin
(Jana and Pahan 2010). Curiously, antibodies to many of these glycosphingolipids, including
sulfatides, have been discovered in the cerebrospinal fluid of MS patients (Ilyas et al. 2003). This
suggests that autoimmunity against glycosphingolipids in MS contributes to the inflammatory
process and disease progression.
Research has demonstrated a strong connection between S1P and MS. S1P levels are
elevated in the cerebrospinal fluid of MS patients (Kułakowska et al. 2010). In addition, S1PR1
and S1PR3 have also been shown to be increased in MS lesions (Van Doorn et al. 2010).
Collectively, this suggests an overall upregulation of S1P signaling in MS. As activation of
S1PR1 can trigger T-cell activation and egress, it is evident that S1P signaling is a factor in the
progressive neuro-inflammation of MS (Maceyka et al. 2012; Tsai and Han 2016). Modulation
of S1PR1 is therefore an important therapeutic strategy for MS. The FDA-approved S1P analog
FTY720 (fingolimod; known by the trade name Gilenya) suppresses S1P signaling in MS and
leads to an alleviation of neuro-inflammation (Rothhammer et al. 2017).
Autoimmune encephalitis is a devastating inflammatory condition of the CNS. It is often
triggered by CNS infections, which can typically be viral but can alternatively be caused by
microbes such as bacteria and fungi (Venkatesan and Benavides 2015). Experimental
autoimmune encephalitis (EAE) is often used as a model system for exploring MS in addition to
its utility for understanding autoimmune encephalitis. In an EAE model, most plasma S1P was
observed to be bound to ApoM in the high-density lipoprotein particle. Importantly, ApoM-S1P
was found to activate the S1PR1/Erk pathway and prevent the differentiation and proliferation of
bone marrow lymphocyte progenitors (Blaho et al. 2015). This study demonstrated that neuro-
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inflammation was amplified in the CNS in EAE mice with an Apom knockout. In contrast, mice
that had elevated levels of ApoM experienced a reduction in neuro-inflammation. In summary,
these data indicate that ApoM-S1P is responsible for mitigating neuro-inflammation in EAE.

1.5.7. Neuropathy
Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is associated with mutations in
genes that encode for SPT subunits (Bejaoui et al. 2002). SPT dysfunction can result in
reductions in complex sphingolipids such as a sphingomyelin (Bejaoui et al. 2002), because it is
responsible for the initial step in de novo ceramide synthesis (Gault et al. 2010). However, total
sphingolipid mass in HSAN1 is usually unchanged due to gain-of-function mutations that allow
SPT to use other amino acids, such as alanine and glycine, instead of serine (Lone et al. 2019;
Penno et al. 2010). This leads to the generation of deoxysphingolipids where the lack of a 1-OH
head group prevents further metabolism to complex sphingolipids (Lone et al. 2019). Neurotoxic
effects have been attributed to deoxysphingolipids, including 1-deoxy-dihydrosphingosine and 1deoxymethyl-dihydrosphingosine, in HSAN1 characterized by mutations in either Sptlc1 or
Sptlc2 (Bode et al. 2016; Ernst et al. 2015; McCampbell et al. 2005; Penno et al. 2010;
Suriyanarayanan et al. 2016). Studies of transgenic mice with a representative SPTLC1 mutant
demonstrated the loss of myelinated axons with age (McCampbell et al. 2005). Additionally, a
recent study demonstrated that exogenous treatment of neuronal cultures with
2+

deoxysphingolipids resulted in neurotoxicity by disrupting Ca and mitochondrial homeostasis
(Wilson et al. 2018). Interestingly, deoxysphingolipids have also been observed to be elevated in
other instances of neuropathy. Docetaxel and paclitaxel chemotherapy-induced neuropathy was
associated with increases in deoxysphingolipids, whereas cisplatin-induced neuropathy was not
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(Becker et al. 2020; Kramer et al. 2015). Similarly, deoxysphingolipids were elevated in the
plasma of type 2 diabetic neuropathy patients (Dohrn et al. 2015) and lowering plasma
deoxysphingolipids improved neuropathy in diabetic rats (Othman et al. 2015).

1.6. Sphingolipids in Inherited Metabolic Disorders (Sphingolipidoses)
Table 1.1 Sphingolipodoses.

1.6.1. Fabry Disease
Fabry disease is a sphingolipidosis with an X-linked mutation in the Gla gene, encoding for αgalactosidase A (αGalA), which leads to an enzymatic deficiency and buildup of
glycosphingolipids in the lysosome (Germain 2010) (Table 1.1.1). Moreover, Fabry disease
patient samples often exhibit signs of neuro-inflammation as part of a pathology leading to stroke
(Kikumoto et al. 2010). Oxidative damage and pro-inflammatory cytokines IL-6 and TNFα have
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been shown to be increased in samples from treated Fabry disease patients with
globotriaosylceramide accumulation (Biancini et al. 2012). Additionally, Fabry disease has also
been shown to be associated with Parkinson’s disease. As with Fabry disease, activity of αGalA
has been shown to be lowered in Parkinson’s disease patient peripheral blood leukocytes (Wu et
al. 2008). Taken together, these studies suggest that excess globotriaosylceramide in Fabry
disease may be responsible for the development of neuro-inflammation.

1.6.2. Farber Disease
Mutations in the Asah1 gene cause a loss of acid ceramidase activity in Farber disease (Bär et al.
2001) (Table 1.1). These mutations to acid ceramidase lead to an accumulation of ceramide in
many organs including the brain (Alayoubi et al. 2013). Inflammatory cytokines causing the
recruitment of neutrophils, monocytes, and macrophages have been shown to be increased in a
model of Farber disease, along with an elevation in C16 ceramide and C16 dihydroceramide
(Dworski et al. 2017). As ceramide can activate a variety of inflammatory signaling pathways,
the excessive storage of ceramide likely contributes to the advancement of inflammation seen in
this condition. In fact, the level of lysosomal ceramide accumulation has been correlated with the
progression of Farber disease symptoms (Levade et al. 1995).

1.6.3. Gaucher’s Disease
Gaucher’s disease is an inherited disorder arising from an autosomal recessive mutation in the
Gba genes which causes a loss of function of respective GCases (Table 1.1). The condition is
characterized by dysfunctional lysosomal storage leading to an excessive storage of
glucosylceramide and higher order glycosphingolipids (Wong and Krainc 2016). There are three

29

types of Gaucher’s disease. Type 1 is the most common, while both Type 2 and Type 3 are rare
and can cause severe CNS symptoms (Paciotti et al. 2020). In a mouse model of Gaucher’s
disease, chronic neuro-inflammation was observed as an increase in the levels of the proinflammatory cytokines TNFα and IL-1β (Vitner et al. 2012). Other studies have also shown that
excessive glucosylceramide in GCase-deficient mouse models can trigger neuro-inflammation
(Farfel-Becker et al. 2014). There have also been studies that have drawn connections between
Gaucher’s disease and Parkinson’s disease through the commonality of increased
glucosylceramide (Neumann et al. 2009; Wong and Krainc 2016). In some Parkinson’s disease
patients, GCase activity is impeded due to mutation in the Gba gene leading to glucosylceramide
buildup similar as with Gaucher’s disease (Nuemann et al. 2009; Wong and Krainc 2016).
Moreover, disruption in GCase processing and trafficking can be directly impaired by αsynuclein, which provides another link between Gaucher’s disease and Parkinson’s disease
(Wong and Krainc 2016).

1.6.4. Krabbe Disease
Krabbe disease is characterized by an autosomal recessive mutation in Galc that causes a
reduction in β-galactosylceramidase (Tappino et al. 2010) (Table 1.1). This leads to an
accumulation of psychosine (also known as galactosylsphingosine) in the lysosome (Chen et al.
2014). In the Krabbe disease brain, psychosine encourages the release of arachidonic acid and
lysophosphatidylcholine in a secretory phospholipase A2-dependent manner, leading to an
induction of oxidative stress in oligodendrocytes (Giri et al. 2006). TNFα is elevated in Krabbe
disease patient samples and can be further increased by the addition of exogenous psychosine
(Pasqui et al. 2007). This highlights a possible mechanism for the role of psychosine in the
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development of neuro-inflammation. Additionally, the Twitcher mouse model of Krabbe disease
has been shown to exhibit elevations in α-synuclein in the brain (Marshall et al. 2018). This
demonstrates a possible pathological connection between Krabbe disease and Parkinson’s
disease.

1.6.5. Metachromatic Leukodystrophy and Multiple Sulfatase Deficiency
In Metachromatic Leukodystrophy, an autosomal recessive mutation in the gene coding for
arylsulfatase A (Arsa) leads to an accumulation of sulfatides alongside decrease in cerebrosides
(glucosylceramide/galactosylceramide) (Eichler and Van Haren 2007) (Table 1.1). It has also
been shown that sulfatide activates the NF-κB pathway and causes phosphorylation of p38, Erk,
and Jnk in primary microglia, uncovering a mechanism for sulfatide-mediated neuroinflammation in Metachromatic Leukodystrophy (Jeon et al. 2008). Similarly, an autosomal
recessive mutation in the gene encoding for sulfatase-modifying factor 1 (Sumf1), which encodes
for an enzyme that post-translationally modifies sulfatases, results in a systemic lack of
sulfatases known as multiple sulfatase deficiency (Annunziata et al. 2007) (Table 1.1). This leads
to excessive storage of glycosaminoglycans and sulfatides in the lysosome (Schlotawa et al.
2020). In a murine model of multiple sulfatase deficiency, inflammatory cytokines were
upregulated in the CNS and apoptosis was increased as the disease progressed, leading to
neurodegeneration (Settembre et al. 2007).
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1.6.6. Niemann-Pick Disease
There are three main forms of Niemann-Pick disease: Types A, B, and C (Schuchman and
Desnick 2017) (Table 1.1). Types A and B Niemann-Pick disease both have mutations impacting
aSMase (Smpd1); however, Type B is non-neurological (Schuchman and Desnick 2017). In
contrast to Type A, Type C Niemann-Pick disease has mutations in the Npc1 or Npc2 genes,
which typically code for a protein located in the lysosome and thought to control lipid trafficking
(Newton et al. 2018). This causes excessive lysosomal storage of cholesterol, sphingomyelin,
and various glycosphingolipids such as GM2 and GM3 gangliosides (Lloyd-Evans et al. 2008).
Neuro-inflammatory markers are observed in both Type C Niemann-Pick disease patient samples
and mouse models (Cologna et al. 2014). Activation of microglia occurs and is responsible for
the development of oxidative stress and neurodegeneration in Type C Niemann-Pick disease, and
can be remedied with anti-inflammatory therapy (Smith et al. 2009). In addition, the TNFα
pathway was found to be upregulated in the brains of a Type C Niemann-Pick disease mouse
model (Wu et al. 2005).

1.6.7. Tay‐Sachs Disease and Sandhoff Disease
In Tay-Sachs disease, a mutation in the Hexa gene encoding for the α subunit of lysosomal βhexosaminidase leads to enzyme loss and an accumulation of GM2 ganglioside (Myerowitz
1997) (Table 1.1). Typical symptoms of this disease include blindness with a characteristic
macular cherry-red spot, loss of hearing, muscle problems, convulsions, and death in early
childhood (Chen et al. 2014). These symptoms are thought to be caused by damaging neuroinflammation due to gangliosidosis. In a mouse model of Tay-Sachs disease, elevated levels of
pro-inflammatory cytokines including TNFα were observed (Seyrantepe et al. 2018). This
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suggests that neuro-inflammation plays a prominent pathological role in Tay-Sachs disease.
Further research is necessary to determine the mechanism in which GM2 gangliosides trigger
this inflammatory response.
Likewise, Sandhoff disease is a GM2 gangliosidosis characterized by a lack of βhexosaminidase (Table 1.1). However, in Sandhoff disease, there is a mutation occurring in the
Hexb gene which encodes for the β subunit. This leads to a deficiency in both β-hexosaminidase
enzymes and triggers GM2 ganglioside accumulation (Breiden and Sandhoff 2020). Sandhoff
disease also has connections with Parkinson’s disease. In a recent study, it was found that mice
deficient in β-hexosaminidase had increased formation of α-synuclein, the toxic protein that
builds up in Parkinson’s disease. When expression of both Hexa and Hexb were increased, αsynuclein embedding was lowered, and neurodegeneration was prevented (Brekk et al. 2020).
The Hexb mutation has also been found in some variants of Parkinson’s disease, further
supporting a connection between the two conditions (Robak et al. 2017).

1.7. Sphingolipids in Viral Infections of the CNS
1.7.1. Zika
Infection by the Zika virus (ZIKV) can cause birth defects, including microcephaly, by impeding
normal brain development (Wang et al. 2018). ZIKV invokes a neuro-inflammatory response in
primary microglia by causing the release of pro-inflammatory cytokines and mediators (Diop et
al. 2018; Wang et al. 2018). ZIKV infection can also infiltrate astrocytes of varying maturation
stages and has been observed to increase the amount of exosome secretion in cortical neurons
(Huang et al. 2018). These infected cortical neurons, as well as the exosomes that they release,
have had increased levels of nSMase2 activity (Zhou et al. 2019). When infected cells were
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treated with the nSMase2 inhibitor GW4869, a reduction in viral RNA and extracellular vesicle
release was observed (Huang et al. 2018; Zhou et al. 2019). This evidence supports a role for
nSMase2 in the propagation of ZIKV infection and its invocation of neuro-inflammation.
Importantly, nSMase2 activity results in the generation of ceramide from sphingomyelin and this
process has been shown to play a role in exosome release (Trajkovik et al. 2008). Additionally, it
has been shown that ZIKV-infected microglial cells exhibited upregulated levels of both
ceramide and sphingosine soon after as well as up to 48 h following infection (Diop et al. 2018).
Altogether, this suggests that therapeutics targeting nSMase2 and its related neuro-inflammatory
pathways may hold potential to treat ZIKV infection.

1.7.2. HIV
Human immunodeficiency virus (HIV) is another viral infection recognized to cause chronic
neuro-inflammation. More so, this can also be associated with alterations in sphingolipid
metabolism. Mouse models of HIV infection demonstrate an increased expression of proinflammatory cytokines and mediators in the brain indicative of a chronic neuro-inflammatory
state (Persidsky et al. 1997). The viral HIV protein, glycoprotein 120 (gp120), is associated with
CXC chemokine receptor 4 (CXCR4) in cultured human primary neurons. This was also shown
to be associated with a redox-sensitive activation of nSMase2, and further production of
superoxide and the induction of apoptosis (Jana and Pahan 2004). HIV-induced activation of
nSMase2 has also been supported by the analysis of HIV patient samples. Increased
sphingomyelinases activity is observed in the cerebrospinal fluid of HIV patients with active
HIV-associated dementia (HIV-D) compared to those with inactive or no dementia (Bandaru et
al. 2007). Furthermore, these studies have shown significant increase in ceramides C18:0, C22:0,
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C24:0, and C24:1 in HIV patients with active dementia. Conversely, patients who had inactive
dementia had higher levels of sphingomyelin (Bandaru et al. 2007). Further studies of HIV-D
patients highlighted that while the conversion of sphingomyelin to ceramide was associated with
swift declines in cognitive ability, an increase in the ratio of sphingomyelin to ceramide was
strongly correlated with the progression of HIV-D (Bandaru et al. 2013). Altogether, this
suggests that neuro-inflammation associated with HIV infection is facilitated by an
inflammation-mediated increase in nSMase2 activity that is associated with ceramide
accumulation and NOX2 activation. However, more studies are needed to fully appreciate the
collective dysregulation of sphingolipid metabolism and progressive neurodegeneration in HIVD patients.

1.8. Therapeutic Advances
1.8.1. S1PR1 Regulation
FTY720 (fingolimod; known by the trade name Gilenya) is an FDA-approved therapy for MS
which exerts its effects in the CNS by antagonizing the S1P signaling pathway. Once
phosphorylated by SPHK2, FTY720 becomes an S1P analog which can modulate multiple
S1PRs (Brinkmann et al. 2002). FTY720 can suppress the autoimmune response in MS because
S1P signaling is associated with T-cell activation and egress (Maceyka et al. 2012; Tsai et al.
2016). This has been prominently demonstrated in the EAE mouse model, where treatment with
FTY720 prevented CD4+ T cells from migrating throughout the spinal cord (Kataoka et al.
2005). Furthermore, studies have suggested that FTY720 may be effective against other neuroinflammatory conditions including Alzheimer’s disease, ALS, Huntington’s disease, NiemannPick disease, as well as spinal cord injury (Jęśko et al. 2020; Potenza et al. 2016; Miguez et al.
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2015; Newton et al. 2017; Lee et al. 2009). Notably, studies have shown that the efficacy of
FTY720 in different models of neurological disorders may be due to non-classical roles for the
drug. Interestingly, in a mouse model of Alzheimer’s disease, FTY720 partly corrected
disruptions in sphingolipid metabolism seen in the disease through a downregulation of CERS
enzymes (Jęśko et al. 2020). However, this effect was only observed at an age of 3 months, while
at age 12 months, an upregulation of the CERS4 enzyme was observed (Jęśko et al. 2020).
FTY720 also was shown to alleviate symptoms of ALS and slow disease progression in an in
vivo model by reducing various mediators of neuro-inflammation (Potenza et al. 2016). In a
Huntington’s disease mouse model, FTY720 prevented astrogliosis and reduced NF-κB
signaling, causing a decrease in pro-inflammatory mediators (Miguez et al. 2015). Additionally,
FTY720 was observed to reduce toxic sphingolipid and cholesterol accumulations in Type C
Niemann-Pick disease (Newton et al. 2017). More classically, FTY720 was shown to alleviate
spinal cord injury in a mouse model by decreasing CD4+ T-cell migration to the injury site (Lee
et al. 2009). These mice were further observed to have hind limb recovery and reduced
hematuria, indicative that antagonizing pro-inflammatory S1P signaling can improve the
prognosis of spinal cord injury recovery (Lee et al. 2009). Overall, FTY720 is a potent
sphingolipid-based therapeutic that may exert efficacy across a range of neurological disorders
that share hallmarks of sphingolipid dysfunction and neuro-inflammation.

1.8.2. Substrate Reduction Therapy and Enzyme Replacement Therapy
Typically, in sphingolipidoses, a sphingolipid accumulates excessively in the lysosome due to a
defective enzyme that catalyzes its breakdown. Substrate Reduction Therapy (SRT) and Enzyme
Replacement Therapy (ERT) are both therapeutic modalities to prevent toxic accumulations of
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sphingolipids and are therefore useful strategies for treating the sphingolipidoses. SRT prevents
the initial formation of the substrate of the defective enzyme to impede its accumulation.
However, finding useful SRTs affecting the CNS has posed a challenge. Although SRTs have
been FDA-approved for the treatment of Type 1 Gaucher’s disease, there are currently no
approved SRTs that effectively alleviate the CNS symptoms of Types 2 and 3 Gaucher’s disease.
Miglustat, an inhibitor of GCS used for Type 1 Gaucher’s disease, is not effective in treating the
neurological symptoms of Type 3 Gaucher’s disease (Schiffmann et al. 2008). Miglustat has also
showed only marginal efficacy in treating infantile Tay-Sachs disease, with treated patients
exhibiting undetectable levels of pro-inflammatory cytokines in the cerebrospinal fluid but not
protected from neurodegeneration (Bembi et al. 2006). The lack of effective SRT options for
CNS-impacting sphingolipidoses may be due to their inability to cross the blood–brain barrier.
Notably, the GCS inhibitor Genz-682452 crosses the blood–brain barrier and has shown some
efficacy in types of Gaucher’s disease that manifest with CNS symptoms. In two different
murine models of Types 2 and 3 Gaucher’s disease, oral administration of Genz-682452 caused a
significant reduction in glucosylceramide in the brain that was concurrent with a reduction in
gliosis (Marshall et al. 2016). Interestingly, excess lysosomal storage was alleviated in Fabry
disease mouse models that also lack the enzymes to catalyze the formation of the
glycosphingolipids, including globosides and isoglobosides, that are otherwise commonly
accumulated in the disease (Porubsky et al. 2014). Genz-682452 also effectively reduces the
levels of globotriaosylceramide and lysoglobotriaosylceramide in the brain and other organs of
Fabry disease mice, with a notably stronger effect observed when treatment is initiated at a
younger age (Ashe et al. 2015). Overall, these studies indicate that SRT may be a useful method
of treating Fabry disease.
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In contrast to SRT, ERT is a treatment strategy where functional and recombinant
versions of enzyme are used to counteract the defective enzymes associated with
sphingolipidoses. ERT has been studied extensively in Types 2 and 3 Gaucher’s disease but with
minimal results. Treatment with recombinant glucocerebrosidases was not able to prevent
neurodegeneration in an infant with Type 2 Gaucher’s disease (Takajo et al. 2020). Similarly,
ERT administered long-term to Type 3 Gaucher’s disease patients of various genotypes was
unable to prevent the progression of CNS symptoms (Sechi et al. 2014). A longitudinal study of
ERT treatment of Fabry disease patients with recombinant α-galactosidase A found that it
likewise did not alleviate disease progression, although it did lower the risk of having secondary
complications (Romback et al. 2013). It should be of little surprise that the greatest impediment
to ERT efficacy in the CNS is likely due to the inability of recombinant enzymes to traverse the
blood–brain barrier. Notably, intra-cerebroventricular injection of recombinant aSMase in a
mouse model of Type A Niemann-Pick disease resulted in enzyme detection throughout the CNS
and a reduction in brain sphingomyelin levels (Dodge et al. 2009). A similar effect was observed
using the Twitcher mouse model of Krabbe disease, where intra-cerebroventricular injection of
β-galactosylceramidase decreased psychosine throughout the brain (Lee et al. 2007).
Collectively, these studies demonstrate that the effective development of ERT and SRT
treatments for sphingolipidoses affecting the CNS requires the development of therapies that can
cross the blood–brain barrier.

1.8.3. Cambinol
GW4869 is well characterized as an effective and non-cytotoxic nSMase2 inhibitor, but
unfortunately, it does not exhibit drug-like properties (Figuera-Losada et al. 2015; Huang et al.
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2018; Zhou et al. 2019). Therefore, development of an inhibitor that is more suitable for use as
neuro-inflammatory therapy is desirable. Cambinol, known for its role as a SIRT1 and SIRT2
inhibitor, has recently become of interest as a potential treatment for neuro-inflammatory
disorders. Addition of cambinol both in vitro and in vivo prevented the release of proinflammatory cytokines suggesting that it may have utility as a neuro-inflammatory therapeutic
approach (Lugrin et al. 2013). Cambinol acted as a non-competitive inhibitor of nSMase2
isolated from rat brain homogenates and primary neurons (Figuera-Losada et al. 2015). This
further indicates that cambinol may bind to the enzyme–substrate complex. In addition, cambinol
has a greater solubility in aqueous solutions as compared with GW4869 while exhibiting equal
nSMase2-inhibitory efficacy (Figuera-Losada et al. 2015). Therefore, cambinol may be a
promising nSMase-targeted therapy for neuro-inflammatory conditions. However, given its
known ability to also inhibit SIRT1 and SIRT2, there is clearly a profound need for further
nSMase2-directed drug discovery.

1.8.4. Natural Products‐Based Drug Discovery Targeting the Sphingolipid‐Mediated NOX2
Daily supplementation of blueberries over a short term was shown to benefit the cognitive
performance of rats in a radial arm water maze, while lowering serum TNFα and nitric oxide
(Shukitt-Hale et al. 2019). Separately, it was shown that extracts of wild Alaskan bog blueberries
(Vaccinium uliginosum) could alleviate TNFα-induced ROS to neuroblastoma cells (Gustafson et
al. 2007). This was shown to be due to a non-antioxidant and non-cytotoxic inhibition of
nSMase2. Further studies showed that nonpolar fractions of wild Alaskan bog blueberries could
prevent the formation of lipid rafts, rendering the cytosolic p67phox subunit unable to bind to
gp91phox in the plasma membrane (Gustafson et al. 2012). Collectively, these studies showed
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that wild Alaskan bog blueberries contain compounds that can inhibit both nSMase2 and NOX2
(Gustafson et al. 2007, 2012). The potent NOX2 inhibitory abilities of wild Alaskan bog
blueberries make them an excellent source for drug discovery of compounds that can mediate
neuro-inflammation.

1.9. Concluding Perspectives
Sphingolipids are more than simple structural components of membranes because they exert
important bioactive roles that influence cellular fate and function. In the CNS, alterations in
sphingolipid metabolism can serve as a hallmark of neurological disorders. One broadly
important role for sphingolipids lies at the juncture between neuro-inflammation and
neurodegeneration. Neuro-inflammation and alterations in sphingolipid metabolism are both
present across numerous neurological disorders including dementias, motor disorders,
autoimmune conditions, inherited metabolic disorders such as the sphingolipidoses, viral
infection, traumatic brain and spinal cord injury, psychiatric conditions, and more. Neuroinflammation is associated with the neurological decline that accompanies these conditions likely
because it triggers degenerative molecular and biochemical pathways. Therefore, the
sphingolipid alterations that are associated with neuro-inflammation should be of little surprise
as inflammation can directly activate the generation of these bioactive mediators. It is these
sphingolipids that subsequently and mechanistically serve to regulate neurodegenerative
processes. Specifically, sphingolipid regulation of neuronal NOX2 activity is positioned as a
direct link between neuro-inflammation and neurodegeneration (Barth et al. 2009, 2012a, b).
Neuro-inflammation promotes nSMase2 and CERK activation to generate ceramide and C1P that
subsequently serve to activate the neuronal NOX2 (Figure 1.3). Engagement of this pathway
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leads to neurodegeneration due to oxidative damage to actin and SPHK1, the later serving to
further reinforce a pro-death sphingolipid phenotype. The identification and prominence of
sphingolipid-mediated NOX2 activity linking neuro-inflammation to neurodegeneration has also
served to reveal a new series of targets for drug discovery. Potential inhibitors of nSMase2 as
well as of NOX2 have been shown to be present in wild Alaskan bog blueberries (Gustafson et
al. 2007, 2012). Further studies are needed to identify, characterize, and develop the compounds
responsible for these inhibitory activities. Drug discovery efforts from other sources may also
reveal other useful inhibitors of the sphingolipid-mediated NOX2 pathway. Collectively,
therapeutic targeting of this pathway holds the potential to disrupt the connection between neuroinflammation and neurodegeneration. Furthermore, regulators of sphingolipid metabolism and
signaling collectively hold promise as neuro-therapeutics given the broad role for sphingolipids
as mediators of neurological disorders.
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CHAPTER 2

TARGETING LIPID RAFTS WITH URSOLIC ACID

2.1. Abstract
Neuro-inflammatory diseases are extremely debilitating and often deadly to the patient. Lipid
rafts are highly structured and ordered microdomains enriched in cholesterol and sphingolipids.
These microdomains serve as a hub for cellular signaling and thus may contribute to
inflammatory processes involved in many neurodegenerative conditions. Targeted therapies
against lipid rafts, then, represent a potential therapeutic avenue for the treatment or prevention
of neuro-inflammation. Many plant-based natural products have promising anti-inflammatory
effects, but in many cases, their mechanism of action must still be elucidated. In this study, the
impact of the anti-inflammatory natural compound ursolic acid (UA) on lipid rafts in neuronal
cells was examined. It was found that UA reduced the formation of lipid rafts in neuronal cells
treated with TNF𝛼. Meanwhile, it modified raft dynamics but did not significantly change the
number of lipid rafts in cells without TNF𝛼 when compared with vehicle control. Taken
together, these results suggest that UA may possess an anti-lipid raft activity that is only
effective during periods of neuro-inflammation.

2.2. Introduction
2.2.1. Lipid Rafts in Neuro-Inflammation and Neurodegenerative Disorders
Neuro-inflammation is a detrimental form of inflammation which typically involves the
microglia and astrocyte cells and is triggered by the release of proinflammatory cytokines such
as interleukins and tumor necrosis factors (TNFs). Consequences include demyelination, damage
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to axons, synapse impairment or loss of function, inhibition of neural progenitor cells to neurons
(neurogenesis), neuronal cell death, and neurodegeneration (Arsenault et al. 2021, Ransohoff
2016, Lyman et al. 2014). Neuro-inflammation plays a role in a large range of neurodegenerative
disorders including inherited lipid storage disorders, dementias, viral infections, motor
conditions, traumatic injuries, and many others. These conditions are often ultimately fatal, and
few treatment options are available (Arsenault et al. 2021). Therefore, further research is needed
to test novel therapies that can prevent or disrupt neuro-inflammation.
Lipid rafts are small (10-200 nm) microdomains which are very structured and ordered
(Tsuchiya and Mizogami 2020). They are heterogenous and highly enriched in cholesterol and
sphingolipids, especially glycosphingolipids (Tsuchiya and Mizogami 2020, Pike 2003).
Increased saturation of the lipids’ fatty acid tails and the abundance of cholesterol makes these
rafts more compact, less fluid, and thus distinct from other parts of lipid membranes. These
microdomains are also hubs for cellular signaling, with many proteins involved in signaling
localized to lipid rafts, such as receptor tyrosine kinases and G-protein coupled receptors (Pike
2003). Due to their commonality and central role in cellular signaling, lipid rafts are involved in
a variety of disease conditions.
Lipid rafts often play important roles in inflammation. Some types of lipid rafts can act as
a scaffold for inflammatory signaling by holding various pro-inflammatory receptors and
signaling mediators; these structures are termed inflammarafts (Miller et al. 2020). Plasma
membrane lipid rafts are necessary for completing the assembly of the pro-inflammatory
NADPH oxidase 2 (NOX2), with ceramide likely mediating the organization of these rafts
(Gustafson et al. 2012). Lipid rafts’ enrichment in cholesterol also facilitates recruitment and
assembly of the NOX2 subunits. The membrane subunits p22phox and gp91phox are localized to
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lipid rafts in a cholesterol-dependent manner (Vilhardt and van Deurs 2004). When neuroinflammation is triggered, the cytosolic NOX2 components p40phox, p47phox, and p67phox move to
the lipid rafts on the cell membrane, where the membrane subunits are located. The completely
assembled NOX2 is then positioned on these lipid rafts during the extent of its functioning
(Miller et al. 2020). Additionally, cholesterol, a major component of lipid rafts, is required for
NOX2 to produce reactive oxygen species (ROS), further substantiating a necessity of lipid rafts
for NOX2-mediated inflammation (Vilhardt and van Deurs 2004).
In Alzheimer’s Disease, lipid rafts are also an extremely important factor. Most fulllength Aβ precursor protein (AβPP) is not found in lipid rafts and is cleaved by 𝛼-secretases for
normal, non-amyloidogenic processing. However, β-site AβPP cleaving enzyme-1 (BACE1) and
γ-secretase enzymes cleave AβPP in an amyloidogenic manner that leads to the formation of
plaques (Rushworth and Hooper 2011). BACE1 and γ-secretase are both post-translationally Spalmitoylated to localize them to lipid rafts, and AβPP is also targeted to lipid rafts through a
direct interaction with cholesterol. Therefore, lipid rafts are a central location for amylogenesis
(Vetrivel and Thinakaran 2010). Lipid rafts may also influence the aggregation of amyloid beta
(Aβ) due their enrichment in gangliosides including GM1 ganglioside, which Aβ has a high
affinity for (Hicks et al. 2012). There is a large body of evidence supporting a crucial role for
lipid rafts in promoting Alzheimer’s Disease pathology, as reviewed in Díaz & Marin 2021 and
Rushworth & Hooper 2011.

2.2.2. Therapeutics Targeting Lipid Rafts
Though diminishing lipid rafts may appear dangerous as they also have a necessary role in
normal cellular signaling, it is observed that in diseases with pathologies involving lipid rafts,
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these microdomains are found in greater levels and with higher stability (Sviridov et al. 2020).
Lipid rafts have recently emerged as a potential therapeutic target for the treatment of
neurological diseases including Niemann-Pick Type C, HIV infection, traumatic brain injury,
neurodegeneration, as well as other conditions including general inflammation and cancer. As
lipid rafts are important for the early stages of neurodegenerative disease progression, targeting
them may be highly beneficial in reducing Aβ aggregation and preventing the process of neuroinflammation.
One classic type of lipid raft-moderating agent is cyclodextrins such as modified betacyclodextrin (MβCD). This drug causes the extraction of cholesterol from cell membranes.
However, the effects of this type of therapeutic can be too powerful; MβCD depolymerizes actin
and removes other lipids including fatty acids and ceramide, which can result in severe cellular
changes (Sorice et al. 2021). A more recently discovered lipid raft modulator is apoA-I binding
protein (AIBP), which promotes the efflux of cholesterol and lowers lipid raft abundance in
microglia to effectively reduce neuro-inflammation in vitro and in the spinal cord in vivo (Woller
et al. 2018, Fang and Miller 2020). Naturally occurring triterpenoids including glycosides from
Panax ginseng and saponin derivatives from Radix bulperi have also demonstrated anti-lipid raft
effects in vitro, highlighting the potential for natural products-based drug discovery to find
therapeutics targeting lipid rafts (Tsuchiya and Mizogami 2020).

2.2.3, Ursolic Acid: A Natural Product with Anti-Inflammatory Potential
Blueberries have been known to have health benefits for centuries, with medicinal use of
blueberries dating back to the Middle Ages. They have antioxidant properties, likely thanks to
their polyphenol content. However, the modern-day processing of blueberries for customers to
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consume more conveniently and access during the off-season can result in a loss of these
polyphenols and possible reduction in these health benefits (Kalt et al. 2007). In addition to
polyphenols, the genus Vaccinium, which contains blueberries and other similar fruits such as
cranberries and lingonberries, has been found to contain many volatile organic compounds,
mostly terpenoids, which vary in type and abundance in different species and cultivars (Sater et
al. 2020).
The health benefits of blueberries include potential anti-neuro-inflammatory effects.
Daily consumption of blueberries by rats helped them to perform better in a radial arm water
maze test which is used to assess spatial learning, reference memory, and working memory
through search for a reward using extra-maze cues. This increased performance was
accompanied by a reduction in serum TNFα and nitric oxide (Shukitt-Hale et al. 2019). Wild bog
blueberries Vaccinium uliginosum have demonstrated the ability to block neuro-inflammation by
inhibiting neutral sphingomyelinase 2 (nSMase2) and reducing ROS levels in TNFα-induced
neuroblastoma cells (Gustafson et al. 2007). Continuation of this research found that only the
nonpolar fraction and not the polar fraction of these blueberries was able to block lipid rafts from
forming, thus preventing cytosolic subunit of NOX2 p67phox from binding the membrane subunit
gp91phox (Gustafson et al. 2012).
Ursolic acid (UA) has been detected in the wild bog blueberry Vaccinium uliginosum as
well as other blueberries (Vrancheva et al. 2021). It is a naturally occurring pentacyclic
triterpenoid found in a wide variety of medicinal plants and fruits. (Fig. 2.1). It has a molecular
formula of C30H48O3, molecular weight of 456.70032 g/mol, and low solubility in water
(Kashyap et al. 2016). UA is biosynthesized from acetyl-CoA, with squalene as its acyclic
precursor before cyclization (Habtemariam 2019). UA is a nonpolar compound, and it is
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typically located in the waxy outer layer or peel of berries including species of cranberries,
blueberries, and sea buckthorn berries (Neto 2011).

Figure 2.1. Chemical structure of ursolic acid.

UA has demonstrated potent anti-inflammatory and antioxidant effects. In a rat model
with liver fibrosis induced by carbon tetrachloride, NOX2, NOX4, NOX1, p67 phox, p47phox, and
Rac1 were upregulated, but were restored to normal expression levels upon treatment with UA
(Gan et al. 2018). Oral administration of 25 mg/kg UA to a murine model of Parkinson’s disease
resulted in reduced levels of TNFα and nuclear factor-kappa B (NF-𝜅B) nearly to that of healthy
mice and lowered interferon-gamma (IFN-γ) and interleukin-12 (IL-12) while anti-inflammatory
cytokines interleukin-10 (IL-10) and interleukin-4 (IL-4) were significantly increased (Rai et al.
2019). In mouse spinal cord injury, oral treatment with UA resulted in motor function restoration
and regrowth of axons, possibly due to the observed reduction in interleukin-6 (IL-6) and TNFα
(Sahu et al. 2018). In pheochromocytoma cells induced with amyloid beta (Aβ), treatment with
UA lowered expression levels of pro-inflammatory inducible nitric oxide synthase (iNOS) and
cyclooxygenase-2 (COX-2), and blocked NF-𝜅B signaling by decreasing phosphorylation of
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upstream kinases Erk 1/2, p38, and Jnk (Yoon et al. 2014). Interestingly, the NF-κB pathway is
activated by sulfatide, leading to phosphorylation of these same upstream kinases p38, Erk, and
Jnk in primary microglia as a mechanism for neuro-inflammation in Metachromatic
Leukodystrophy (Jeon et al. 2008). This could represent a potential disease application for UA.
In Alzheimer’s Disease, UA may prevent amyloid beta from binding to CD36, a receptor that
triggers downstream reactive oxygen species and proinflammatory cytokine production
(Wilkinson et al. 2011). UA has also shown promising neuroprotective effects in brain injury,
cerebral ischemia, anxiety, and depression (Habtemariam 2019). In addition to anti-inflammatory
effects, UA has also demonstrated efficacy against problems such as cancer metastasis, tumor
angiogenesis, microbial infection, and more (Kashyap et al. 2016). Therefore, research on UA is
of scientific interest and may be beneficial for a wide variety of biomedical applications.
Evidently, the anti-inflammatory potential of UA is promising. However, the specific
mechanism of action for UA is unknown. The goal of this experiment was to investigate the
effects of UA treatment on lipid rafts in neuronal cells, The rationale for this experiment stems
from previous natural products-based drug discovery efforts. The formation of lipid rafts is
important for NOX2 activation (Miller et al. 2020) and nonpolar fractions of blueberry extracts
have previously demonstrated the ability to decrease lipid rafts in vitro (Gustafson et al. 2012).
UA is found in Vaccinium uliginosum and is a nonpolar molecule (Vrancheva et al. 2021).
Hence, it may be responsible for the anti-lipid raft and anti-neuro-inflammatory effects of the
nonpolar blueberry extracts previously described (Gustafson et al. 2007, 2012). Therefore, it was
hypothesized that UA would be able to prevent lipid raft formation in vitro.
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2.3. Materials & Methods
2.3.1. Cell Culture & Treatments
SH-SY5Y neuroblastoma cells (ATCC) were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) with 4.5 g/L glucose and without L-glutamine (Lonza) with 10% v/v Fetal Bovine
Serum (Peak Serum). Cultures were incubated at 37 °C and 5.0% CO2. Cells were detached from
their flasks using a minimal amount of trypsin. The cultures were then plated on poly-D-lysine
coated #1.5 (170 𝜇m thick) German glass coverslips inside of 6-well culture plates and grown at
37 °C and 5.0% CO2 for 24 hours. Next, the cells were serum starved overnight (12 hours) by
removing the media, washing 3 times with PBS, then adding serum-free culture media (DMEM)
and incubating at 37 °C and 5.0% CO2. Following starvation, cells were left untreated as a
control, or 5 µg/mL ursolic acid in dimethyl sulfoxide (DMSO) or an equivalent of volume pure
DMSO was added to the cultures, which were then incubated at 37 °C and 5.0% CO2 for 1 hour.
Next, cells were incubated with 200 ng/mL TNF𝛼 dissolved in 1X PBS with 0.1% bovine serum
albumin (BSA) carrier protein for 30 minutes, or incubated without any additional treatment for
30 minutes, before proceeding to preparation of slides. Each treatment was performed in
triplicate, and two biological replicates of the experiment were performed.

2.3.2. Slide Preparation
Following treatments and 1-hour incubation, cells on coverslips were labeled for lipid rafts using
the Vybrant Alexa Fluor 555 Lipid Raft Labeling Kit (Invitrogen) following the manufacturer’s
instructions. Next, the coverslips were mounted to standard glass microscope slides using
ProLong Glass Antifade Mountant (Invitrogen) following manufacturer instructions. Slides were
cured overnight at room temperature away from light.
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2.3.3. Confocal Microscopy
Images were acquired (60x, oil) using a confocal microscope (Nikon A1R Laser Scanning
Confocal Fluorescence Microscope) equipped with an Ar laser with filter combinations for Alexa
Fluor 555 (555 absorption, 565 emission). Acquisition conditions (detector gain, offset, and
percentage of laser hitting sample) remained unchanged for imaging of each sample to ensure
consistency. Z-stack was utilized to create a maximum intensity projection of the entire cell
thickness (approximately 2 µm). Random fields of view were used to analyze at least 3 cells
from each set of treatment conditions (lipid raft platforms= red).

2.4. Results
In untreated SH-SY5Y cells, lipid rafts are present in moderate quantities and are evenly
dispersed throughout the cell (Figure 2.3A). The addition of UA (Figure 2.3B) appears to alter
the membrane dynamics and cause the lipid raft microdomains to be more spread out. Lipid rafts
in normal cells treated with DMSO vehicle control are more concentrated to specific regions of
the cell (Figure 2.3C). As expected, treatment with TNF𝛼 caused a significant increase in lipid
raft content, with small, abundant lipid raft domains present throughout the cell membrane with a
strong intensity (Figure 2.3D). UA diminished the lipid rafts in these inflamed cells back to that
nearly of cells without TNF𝛼 (Figure 2.3E), causing a dispersion pattern like that observed in the
normal cells treated with the DMSO solvent alone. Meanwhile, the DMSO solvent control did
not appear to significantly reduce the number or dispersion of lipid rafts in these TNF𝛼-treated
cells (Figure 2.3F). Additional images can be found in Appendix Figure A1. Overall, UA
changes lipid raft membrane dynamics in neuronal cells, with differential effects in normal cells
versus cells treated with TNF𝛼.
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Figure 2.3. Ursolic acid effects on lipid rafts in SH-SY5Y cells. In normal culture conditions,
cells possess only a small amount of lipid rafts (red fluorescence) (A). Ursolic acid (UA) changes
the membrane dynamics in normal cells and causes them to become more dispersed (B). Vehicle
control treatment resulted in more concentrated lipid raft domains (C). TNF𝛼 induced a large
amount of lipid rafts throughout the entire cell membrane (D). In these TNF𝛼-treated cells,
ursolic acid reduced the amount of lipid rafts (E), while the vehicle control did not (F).

2.5. Discussion
The goal of this study was to elucidate the effects of UA on lipid raft formation in neuronal cells.
Here, it is shown that UA alters membrane dynamics in SH-SY5Y cells by changing the amount
and dispersion of lipid raft microdomains, with differential results in TNF𝛼-treated cells versus
cells without added TNF𝛼. UA disrupts the normal effects of TNF𝛼 on lipid rafts and restores
the lipid raft dynamics of the cell to a state similar to that of normal cells. However, UA also
appears to modify membrane dynamics in normal cells, albeit in a different manner than in
TNF𝛼-treated cells, potentially by causing lipid raft microdomains to become more spread out.
Lipid rafts are important for several normal cellular signaling pathways (Pike 2003).
However, they also play a pathological role in many neurodegenerative diseases (Díaz and Marin
2021, Rushworth and Hooper 2011, Vilhardt and van Deurs 2004). Therefore, it is important that
therapeutics against lipid rafts can preserve normal physiologic functioning of cells while
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blocking pathologic functions of lipid rafts (Sviridov et al. 2020). Due to these differential
effects observed, UA may be very useful as a treatment for neuro-inflammatory conditions and
other diseases where lipid rafts are involved. Additional research may focus on uncovering the
downstream consequences of the observed lipid raft modulation by UA.
The BSA carrier protein was added to the lyophilized TNF𝛼 according to the
manufacturer instructions for reconstitution. BSA and other carrier proteins are useful for
enabling lipophilic drugs to enter or cross the cell membrane, as well as for long-term storage of
proteins at low concentrations (<1mg/mL), wherein the protein may degrade, become
inactivated, or become attached to the surface of the storage container during repeated freezethaw cycles (Makriyannis et al. 2005). In these cases, it is common practice to add a carrier
protein to improve storage. However, BSA was not necessary for this experiment, as TNF𝛼 does
not need a carrier to become soluble, and it was utilized immediately after reconstitution.
Therefore, the results with TNF𝛼 added are not physiologically accurate and are only a
suggestion of what may occur; to confirm the effects, the experiment may be repeated in the
future using a carrier-free TNF𝛼.
Drug delivery is an important part of ensuring therapeutic success, and brain-directed
therapeutics can be particularly difficult to develop. The blood-brain barrier (BBB) poses a
unique challenge in delivering therapies to the brain, as this barrier prevents a vast majority of
molecules from entering the brain as a neuroprotective function (Abbott 2013). As this study was
performed in vitro using traditional cell culture methods, the BBB was not present in this model.
Small molecules that are lipid-soluble and have a molecular mass under about 400-600 g/mol can
cross the brain endothelium that forms the BBB via lipid-mediated transport (Abbott 2013,
Pardridge 1998). Therefore, it may be reasonably postulated that UA could potentially cross the
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BBB, as it is lipophilic with a molecular mass of 456.7 g/mol (Kashyap et al. 2016). Future
research needs to examine the BBB permeability of UA to determine if it can successfully cross
the BBB and exert its effects on inflamed neurons in the brain. In vivo studies would enable this
hypothesis to be tested.
The development of novel therapies based on natural products is not a new strategy.
Since the dawn of civilization, items derived from nature such as plants, animals, and minerals
have been used to treat human disease and are still utilized in many traditional medicine
practices today (Lahlou 2013). In the pharmaceutical industry, compounds found in nature still
form a major basis of drugs eventually brought to the market. In fact, of all the approved smallmolecule drugs in the almost 39 years from January 1981 to September 2019, 930 out of 1,394
(66.7%) are all-natural, natural product derivatives or mimics, botanical drugs, or synthetic drugs
with a pharmacophore from a natural product. Over this same time frame, most approved
medications for Alzheimer’s Disease, Gaucher’s Disease, Parkinson’s Disease, and Multiple
Sclerosis are of this same natural or naturally derived category rather than being totally synthetic
(Newman and Cragg 2020). Evidently, investigating natural products such as UA is a worthwhile
and promising venture. It is possible that with extensive future research, UA, a UA derivative, a
UA mimic, or a synthetic drug with a UA pharmacophore could eventually become an approved
treatment for neuro-inflammation.
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CHAPTER 3

STRUCTURAL ROBUSTNESS OF PROTEIN SERINE PHOSPHATASE RSBX

3.1. Abstract

Proteins regulate countless cellular processes, including functions necessary for survival, and
detrimental effects such as uncontrolled inflammation and cell death. Protein folding is of utmost
importance to biological function; when a protein is denatured or misfolded, its normal
functionality is lost, and this can often lead to serious diseases and complications. RsbX is a
PP2C-family serine phosphatase important for the stress response of Bacillus subtilis. It has a
high level of structural homology to human protein phosphatase 2C (PP2C). PP2C can be
activated by the sphingolipid ceramide and is a powerful regulator of cell survival and insulin
signaling which may have a role in neurodegenerative diseases. Drug discovery efforts have been
ongoing to target PP2C, but there is no approved therapeutic antagonist of this protein to date. In
this research, the effects of the anti-neuro-inflammatory molecule ursolic acid (UA) on the
secondary structure of RsbX were investigated using circular dichroism (CD) spectroscopy.
Expression and purification protocols were successfully designed to produce high quantities of
RsbX, and the thermodynamic properties of this native protein were characterized using CD with
thermal denaturation, prior to studies of the effects of UA on RsbX folding. It was found that
there is no significant impact of UA on the secondary structure of RsbX. These results indicate
that disruption of protein serine phosphatase folding is likely not a part of UA’s mechanism of
action against neuro-inflammation. Methods developed in this study have applications for studies
of countless other proteins of B. subtilis, as well as proteins from different organisms.
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3.2. Introduction
3.2.1. Protein Expression in Bacterial Systems
To study the surrogate serine phosphatase RsbX, it was necessary to produce it in high
quantities. Recombinant expression of proteins in bacterial systems is a reliable and efficient
method for protein production. Escherichia coli is commonly used for protein expression due to
its relatively quick growth, ease of use, cost-effectiveness, and versatility in media selection
(Lozano Terol et al. 2019, Baneyx 1999). For this project, the BL-21(DE3) strain of E. coli was
utilized. This is a strain specifically designed for recombinant protein expression, which lacks
lon and ompT proteases to reduce protein degradation. It also contains a prophage called DE3,
which possesses the gene for T7 RNA polymerase under control of the lacUV5 promoter (Jeong
et al. 2015).
Plasmids such as the popular pET expression vectors, which contain protein-encoding
genes downstream of the bacteriophage T7 late promoter, can be easily transformed into BL21(DE3) cells. Expression of the protein of interest is then induced by the addition of isopropylβ-D-1-thiogalactopyranoside (IPTG). IPTG is a lactose analog, and functions by binding to the
lac repressor. This triggers expression of the T7 RNA polymerase by enabling activation of the
lacUV5 promoter, leading to subsequent transcription and translation of the protein-encoding
genes. The protein-encoding genes are overexpressed, as IPTG is unable to be metabolized by E.
coli, leading to production of the desired protein at high concentrations (Baneyx 1999).
Various affinity tags may be affixed onto proteins for purification, often with a linker region
containing a cleavage site to later remove the tag. The tobacco etch virus (TEV) protease has a
very high sequence specificity, allowing it to be used to cleave fusion proteins or affinity tags
from proteins of interest without entirely degrading the proteins (Kapust and Waugh 2000). For
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this project, plasmids were designed to include N-terminal 6-Histidine tags followed by a TEV
recognition sequence before the sequence encoding each protein. However, it was ultimately
determined that the 6-His tags would not be removed from the proteins prior the thermal
denaturation studies, due to the tags having little to no effect on native structure (Carson et al.
2007) and only minute changes to thermal stability and melting temperature (Booth et al. 2018).

3.2.2. Nickel Affinity Chromatography
Affinity chromatography is a very versatile technique which relies on biochemical interactions
between molecules such as ligand-receptor, enzyme-substrate, and antibody-antigen. In this
method, the stationary phase consists of a ligand known to bind to the protein of interest. The
sample is allowed to flow through the column, causing only the desired proteins to be bound to
the stationary phase. The mobile phase is then adjusted to trigger the protein to elute. This
elution can be performed through specific elution, where an agent that competes for the ligand is
added in a high concentration, or nonspecific elution, where solvent conditions are changed to
weaken the protein-ligand interaction, such as by changing pH or ion conditions, or by causing
the protein to unfold (Urh et al. 2009). Recombinant proteins may be specifically designed for
affinity chromatography, such as by including an affinity tag in their sequence or expressing it as
a fusion protein bound to a tag such as small ubiquitin-like modifier (SUMO), thioredoxin (Trx),
or maltose-binding protein (MBP) that is optimal for the selected affinity chromatography. In
these cases, a cleavable sequence that is recognized by a specific protease is included in the
sequence so the tag can be removed after purification. An additional round of purification may
then be needed to remove the cleaved tag from the pure protein in solution (Wood 2014,
Kinsland 2010).
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Affinity chromatography that utilizes transition metal ions such as Co2+, Ni2+, Cu2+, or
Zn2+ in the stationary phase is called immobilized metal-affinity chromatography (IMAC). In
nickel affinity IMAC, the stationary phase contains a nickel-nitrilotriacetic acid matrix (Ni2+NTA). The NTA is securely attached to the column resin, while the Ni2+ ion is chelated with the
NTA through 4 of its 6 coordination sites, while the other 2 sites are free to interact with a tagged
protein (Bornhurst and Falke 2010).
The undoubtedly most popular affinity tag for IMAC is the histidine tag (His tag), which
consists of 6-10 consecutive histidine (His) residues at the N- or C-terminus of the protein. This
amino acid is the one that most strongly interacts with Ni2+ and other transition metal ions (Wood
2014, Bornhurst and Falke 2010, Kinsland 2010). The electron donor groups on histidine’s
imidazole ring can easily bond with the free coordination sites of the Ni2+, making the protein
bind to the column (Figure 3.1) (Bornhurst and Falke 2010). An optimal pH for binding of the
His tag is neutral to slightly basic (commonly between pH 7.5 to 8.0 (Kinsland 2010).

Figure 3.1. Schematic of histidine and NTA chelation with a Ni2+ ion. This occurs during
nickel-affinity IMAC. Black bar represents the stationary phase that the NTA is bound to.
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To elute the protein, the pH can he adjusted to become more acidic (pH 4.0-5.3), which
causes protonation of the nitrogen atom in the imidazole ring of the His residue, disturbing its
bond with the column matrix; however, this method may damage the protein.
Ethylenediaminetetraacetic acid (EDTA) could be added instead to strip the column, but this
causes contamination of the protein eluent with the Ni2+-NTA. Most commonly, the protein is
eluted by adding a high concentration of imidazole, the main functional group of histidine. The
imidazole competes to bind to the resin, pushing the protein off the column due to its much
higher concentrations (Bornhurst and Falke 2010, Kinsland 2010). Imidazole concentrations of
100 mM or greater are ideal for elutions from Ni2+-NTA resin; 10-50 mM imidazole may also be
added to the washing buffer to prevent nonspecific binding (Bornhurst and Falke 2010).

3.2.3. Methods of Measuring Protein Thermal Denaturation
There are many techniques available for the study of protein stability. Overall stability of
proteins is typically measured using an increasing ramp of temperature or adding varying
concentrations of denaturant. Thermal unfolding is significantly more cooperative than chemical
unfolding (Li-Blatter and Seelig 2019). These denaturation experiments allow for the assessment
of protein stability; for instance, more thermodynamically stable proteins will be more resistant
to unfolding induced by heat. Common methods for these experiments include differential
scanning calorimetry, mass spectrometry, and circular dichroism.
Differential scanning calorimetry (DSC) directly measures the heat capacity of a sample
relative to an increasing temperature by measuring the difference in power between a reference
cell lacking protein and the sample cell, then converting this signal to heat capacity. From this
information received by the calorimeter, the enthalpy (∆H) and melting temperature (Tm) of the
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analyte can be calculated. Thus, a benefit to DSC for protein thermal stability determination is
that it can find the change in specific heat capacity, and thus result in more accurate calculations
of thermodynamic properties (Li-Blatter and Seelig 2019, Johnson 2013, Wen et al. 2012).
Mass spectrometry (MS) is a method for assessing protein stability with applications for
proteome-wide approaches. In the limited proteolysis and mass spectrometry (LiP-MS)
approach, protein structural changes are assessed via quantification of the change in sensitivity to
a protease in varying conditions such as changing temperatures (de Souza and Picotti 2020,
Leuenberger et al. 2017). One recent study of thermal denaturation of Escherichia coli,
Saccharomyces cerevisiae, Thermus thermophilus, and human cells using LiP-MS revealed that
at a temperature which caused physiological impairment to the cells, a group of essential proteins
was denatured. In all 4 cell types, a direct relationship was also observed between protein
thermodynamic stability and abundance, supporting the translational robustness hypothesis, and
suggesting that during the evolutionary timeline, abundant proteins became more
thermodynamically stable to reduce the burden of protein misfolding (Leuenberger et al. 2017).
An additional MS-based approach to study thermal denaturation is thermal protein profiling
(TPP). In this approach, cells or lysates are incubated at various temperatures of a temperature
gradient and then centrifuged. As proteins unfold, they become insoluble because their
hydrophobic residues become exposed to the solvent, leading to loss of solubility and
aggregation. Thus, the proteins in the supernatant have remained soluble and are quantified by
MS (de Souza and Picotti 2020). TPP is very useful for studying the entire proteome of a cell and
found that in bacteria, proteins in the same complex have very similar melting temperatures
(Mateus et al, 2018, Tan et al. 2018).
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Circular dichroism (CD) is also extremely useful for protein thermal stability studies.
Increasing temperature while running CD spectroscopy causes more peptide units to be unfolded
as the protein is denatured, reducing the intensity of the spectra over time, representing collapse
toward a random coil (Seelig and Schönfeld 2016, Greenfield 2004). Data analysis can be
performed using either the two-state model or the more complex Zimm-Bragg theory. The twostate model assumes that the protein only exists in 2 forms: folded and unfolded, that at a low
temperature the amount of unfolded protein is negligible, and that at a high temperature the
protein is completely unfolded. When considering a two-state model, the ∆G of a protein
unfolding to a denatured state/refolding to a native state can be calculated from CD
measurements using changes in CD signal intensity as a function of temperature or amount of
denaturant. The change in specific heat is removed from the equation as this cannot be measured
with CD (Li-Blatter and Seelig 2019, Seelig and Schönfeld 2016, Greenfield 2004, 2006a, b).
CD graphs of protein denaturation typically display an isodichroic cross-over point, which is the
point at which the unfolded and folded states of the peptide units in a protein exist in equal
concentrations. As the protein is denatured, the intramolecular equilibrium which generated the
isodichroic point is shifted from the folded to unfolded conformation of peptide units (Seelig and
Schönfeld 2016). The Zimm-Bragg theory was developed for the α-helix to random coil
transition and is used for synthetic polypeptides, but not traditionally used for protein unfolding
data (Li-Blatter and Seelig 2019, Seelig and Schönfeld 2016). However, the Zimm-Bragg model
may be more reliable for calculations in some cases as it provides a more sequential model of
unfolding (Seelig and Schönfeld 2016).
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3.2.4. Circular Dichroism Spectroscopy to Study Protein Folding
CD is a spectroscopic technique used to study proteins in solution which relies on the rotation of
circularly polarized light by chiral compounds. Left-handed (rotating counterclockwise) and
right-handed (rotating clockwise) light with equal magnitudes are shined at the sample. When the
left- and right-handed light are absorbed equally, linearly polarized light results, causing no CD
signal (Figure 3.2A). However, when they are unequally absorbed, elliptically polarized light is
the result, and a CD signal is observed (Kelly et al. 2005) (Figure 3.2B). Due to CD relying on
this unequal absorption, it can be categorized as a special type of absorption spectroscopy
(Sreerama and Woody 2004). Analytes that produce a CD signal are chiral (optically active).
Chiral molecules have nonsuperimposable mirror images and possess one or more chiral centers.
Enantiomers display CD spectra that are mirror images.

A

B

ER + E L

EL

ER

Figure 3.2. Equal versus unequal absorbance of circularly polarized light. (A) The
absorbance of left- (EL) and right-handed (ER) circularly polarized light is equal, leading to the
resulting light (ER + EL) becoming linearly polarized. (B) The left- and right-handed circularly
polarized light are unequally absorbed, causing the formation of elliptically polarized light, with
a shape defined by the sum and difference of the magnitudes of the left- and right-handed
circularly polarized light. The degree of ellipticity (𝜃) is defined by the angle tangent of the
minor (IR-IL) and major (IR+IL) axes.
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CD is useful for the study of chirality in small molecules, as well as looking at protein
structure. Proteins contain many different chromophores which absorb the circularly polarized
light from CD such as aromatic side chains, disulfide bonds, and peptide amide bonds (Kelly et
al. 2005). Different secondary structures have varying characteristic CD spectra: α-helices have a
positive peak at 193 nm and negative peak at 222 and 208 nm, β-sheets have a positive peak at
195 nm and negative peaks at 218 and 195 nm, and random coils or disordered proteins have
negative peaks at 195 nm and lack ellipticity over 210 nm (Figure 3.3) (Wei et al. 2014,
Greenfield 2006c). Native and denatured states of peptide units within a protein also have
different CD spectra, due to their differing conformations.

Figure 3.3. Characteristic CD spectra for common secondary structures. Alpha-helix, betasheet, and random coils display differing spectra in the far UV range (Wei et al. 2014).
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CD data can be reported in several different ways. The difference in absorbance of leftversus right-handed light at a specific wavelength is known as CD, ΔA, or Δ𝜀, and is calculated
by subtracting the extinction coefficient for the right-polarized right from the extinction
coefficient for the left-polarized light at any given wavelength (Δ𝜀 (𝜆) = 𝜀𝐿 (𝜆) − 𝜀𝑅 (𝜆), where
𝜀𝐿 and 𝜀𝑅 are the extinction coefficients for the left- and right- handed light at the wavelength 𝜆).
CD is reported in units of M-1·cm-1. Another common unit for CD data is the degree of ellipticity
(𝜃) in mdeg, which is the angle that has a tangent equivalent to the ratio of the minor to the major
axis of the ellipse (Figure 3.1B). Linearly polarized light has a 𝜃 of 0 mdeg, while left-circularly
polarized light has 𝜃 of +45 mdeg, and right-circularly polarized light has 𝜃 of -45 mdeg. When
a compound equally absorbs both directions of circularly polarized light, the sum is a 𝜃 of 0
mdeg, and therefore only linearly polarized light hits the detector, resulting in no CD signal
(Figure 3.2A). Molar ellipticity ([𝜃]) includes an adjustment for the path length in centimeters (l)
and molar concentration of the sample (C): [𝜃]=100 𝜃/Cl, in the equivalent units of
deg·cm2/dmol or deg/M·m. This formula utilizes Beer’s Law, which CD signals obey, meaning
the intensity of CD signal is proportional to the concentration of chiral molecules present in the
sample. Molar ellipticity and CD can be interconverted using the following conversion: [𝜃]=
3298.2Δ𝜀 (Greenfield 2006c, Sreerama and Woody 2004, Drake 1994).

3.2.5. Translational Robustness Hypothesis
The protein utilized in this research is also being studied in the larger framework of investigating
translational robustness. Over time, proteins may evolve through changes in their amino acid
sequence as encoded in the organism’s genetic material. The rate of evolution has been shown to
have great variation for different proteins, with some proteins remaining unchanged for long
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periods of time, and others evolving much more rapidly (Zuckerkandl & Pauling 1965, Li et al.
1985). Protein evolution rates are extremely useful for determining which proteins in a cell or
pathway or which domains of a protein are most important for normal functioning of the system.
In molecular evolutionary theory, it is hypothesized that more conserved components are more
important for the function of an organism (Lynch 2007).
The translational robustness hypothesis states that proteins are under selective pressures
to fold into their native structure regardless of translational errors, since protein synthesis,
refolding, and degradation are energy-costly processes, and protein aggregates may be toxic to
cells. Concordantly, proteins that are highly expressed would be under greater selective pressure
to avoid translational errors because an increased translation rate would mean a greater
consequence for misfolding. This suggests that proteins expressed at higher levels are more
evolutionarily conserved (Drummond et al. 2005). Research studies of thermal denaturation of
Escherichia coli, Saccharomyces cerevisiae, Thermus thermophilus, and human cells using
limited proteolysis and mass spectrometry (LiP-MS) revealed that while other proteins degraded,
a group of essential proteins remained stable until a temperature which caused physiological
impairment to the cells. In all 4 cell types, a direct relationship was also observed between
protein thermodynamic stability and abundance, supporting the translational robustness
hypothesis, and suggesting that during the evolutionary timeline, more abundant proteins became
more thermodynamically stable to reduce the burden of protein misfolding (Leuenberger et al.
2017). In the Varga Lab, the thermodynamic properties of approximately 25 total proteins from
Bacillus subtilis will be studied in order to address the translational robustness hypothesis.

64

3.2.6. Human Protein Phosphatase 2C
Approximately 1/3 of human intracellular proteins are subject to regulation by phosphate,
making enzymes that modify protein phosphorylation extremely important (Rogers et al. 2006).
Protein dephosphorylation in humans is mainly accomplished by serine/threonine protein
phosphatases (PPs), for which there are two unrelated gene families: the PPP family which
consists of PP1, PP2A, and PP2B subfamilies, and the metal-dependent protein phosphatase
(PPM) family which are all structurally related to protein phosphatase 2C (PP2C) and consists of
PP2C, PHLPP, PPM1, and more (Kamada et al. 2020, Rogers et al. 2006, Andreeva et al. 2001).
The crystal structure of human PP2C (PDB ID 1A6Q) contains a catalytic domain at the Nterminus from residues 1-290 with a central 𝛽-sandwich surrounded by 𝛼-helices (Das et al.
1996, Barford et al. 1998). This is very similar to the tertiary structures of the PPP family,
leading to these two families being hypothesized to have the same mechanism of catalysis
despite originating from different gene families (Barford et al. 1998). Unlike the PPP
phosphatases, PP2C relies on Mg2+ or Mn2+ for its catalytic activity. This metal cation helps to
coordinate the phosphate ion at the catalytic site; it is necessary for the phosphatase activity of
PP2C (Das et al. 1996). There are at least 22 different isoforms of PP2C possible in humans
(Lammers and Lavi 2007).
The alpha isoform of PP2C (PP2C𝛼) is the most studied isoform. PP2C𝛼
dephosphorylates and therefore inhibits cell cycle checkpoints such as cyclin dependent kinases
(CDKs), AMP-activated protein kinase (AMPK) and the mitogen activated protein kinases
(MAPKs) activated by cytokines such as tumor necrosis factor 𝛼 (TNF𝛼) in the p38 and JNK
pathways (Ofek et al. 2003, Rogers et al. 2006, Takekawa et al. 1998). PPC2𝛼 inhibition of
MAPKs is thought to be at the MAPKK or MAPK level (Takekawa et al. 1998). These pro-
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apoptotic effects have been observed in neuronal cells, where PP2C𝛼 was found to be necessary
for apoptosis induction by the unsaturated fatty acid oleic acid in SH-SY5Y cells (Schwarz et al.
2006).
PP2C𝛼 has contrasting effects on insulin signaling in different cell types. In adipocytes, it
serves as a positive regulator of insulin signaling by directly increasing the activities of
phosphinositise-3-kinase (PI3K) and enhancing downstream effects such as phosphorylation of
Akt (Yoshizaki et al. 2004). However, in neurons, PP2C negatively regulates insulin signaling
and has been shown to dephosphorylate the downstream targets of Akt, AS160 and GSK3𝛽, in
differentiated Neuro-2a cells during insulin stimulation (Yadav et al. 2019).
The epsilon isoform of PP2C (PP2C𝜖) is a transmembrane protein in the endoplasmic reticulum
(ER) with its catalytic domain in the cytosol. PP2C𝜖 has demonstrated the ability to
dephosphorylate ceramide transport protein (CERT), causing it to be redistributed to the Golgi
from the cytosol and thus may have a role in trafficking ceramide from the ER to the Golgi
(Saito et al. 2007).
The regulation of AMPK by PP2C is perhaps one of its most important and
neurologically relevant features. The phosphorylation of Thr172 in the catalytic subunit of
AMPK is necessary for activation; when this residue is phosphorylated, AMPK activity increases
nearly 100-fold. PP2C is an inhibitor of this enzyme and removes the phosphate from Thr172 to
keep AMPK in an inactive state. Thus, PP2C inhibition of AMPK is very potent (Peixoto et al.
2017). AMPK inhibition has a potential role in promoting the pathogenesis of Alzheimer’s
Disease, with AMPK activity demonstrating significant decreases in the Alzheimer’s brain.
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3.2.7. Sphingolipid Regulation of PP2C
The hypothetical center of sphingolipid metabolism ceramide has profound cellular effects,
including widely appreciated promotion of apoptosis and cellular stress (Arsenault et al. 2021). It
has long been known to target several serine/threonine phosphatases, including PP1 and PP2A
(Chalfant et al. 1999). More recently, it was determined that ceramide also activates PP2C𝛼. In
particular, the erythro conformation of C6 and C16 ceramide were found to be activators. It does
so by directly impacting the enzyme, potentially allosterically, and not by affecting its affinity
for substrate. These effects were discovered in rat brains and A-549 cells, wherein PP2C only
dephosphorylates the representative substrate phospho-P38𝛿 when ceramide is present.
Interestingly, other sphingolipids were also found to regulate PP2C𝛼: dihydro C16 ceramide also
activated it, while sphingosine demonstrated inhibitory effects (Perry et al. 2012).

3.2.8. Targeting PP2C
To date, there are no FDA-approved therapeutics targeting PP2C, although drug discovery
efforts have been ongoing, especially with naturally occurring molecules. Sanguinarine is a plant
alkaloid which specifically inhibits PP2C but not PP1, PP2A, or PP2B in vitro. When
sanguinarine was added to HL-60 leukemia cells, it induced apoptosis of the cancer cells through
activation of caspase 3/7 in a mechanism involving phospho-p38, a substrate for PP2C (Aburai et
al. 2010). Today, sanguinarine is used experimentally as a standard pharmacological inhibitor of
PP2C in experiments. Quercetin is flavonoid found in several plants and foods which has also
demonstrated effects against PP2C. In aged mice fed on a high-cholesterol diet, quercetin
improved cognitive performance, reduced expression of fatty acid synthase (FAS) and β-amyloid
converting enzyme 1 (BACE-1), and lowered levels of brain cholesterol and amyloid-beta (A𝛽).
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This was found to be due to a downregulation of PP2C by quercitin, leading to a reduction in
activated microglia, TNF𝛼, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2),
and interleukins IL-1𝛽 and IL-6. This led to an inhibition of nuclear factor-kappa B (NF-𝜅B) p65
nuclear translocation and activation of AMPK among many other effects. An AMPK inhibitor
weakened these neuroprotective effects when co-administered with quercetin, showing that
AMPK activation mediates quercetin’s effects (Lu et al. 2010). Screening approaches to identify
potential inhibitors of PP2C found mostly molecules with fused ring groups, especially 2- and 3ring systems, which can bind PP2C near the substrate binding site (residue Arg33) (Rogers et al.
2006).

3.2.9. Bacillus subtilis and RsbX as a Surrogate of Human PP2C
Bacillus subtilis is a spore-producing Gram-positive bacterium. It is typically known as being
soil-dwelling but can also be found in a variety of other locations such as aquatic environments
and within the gastrointestinal (GI) tract of many wild animals. In general, B. subtilis is known to
be non-pathogenic. Due to its presence within the GI tract and feces of animals, as well its nonpathogenicity, it has been studied for its potential as a probiotic for humans and other animals
(Earl et al. 2008). B. subtilis has been found to be safe as an oral probiotic for human
consumption through in vitro research, animal studies, and human trials (Lefevre et al. 2017,
Hong et al. 2008). Currently, there are many commercially available probiotics containing strains
of this bacterium (Ritter et al. 2018). B. subtilis can form biofilms: complex structures wherein
bacteria aggregate and are surrounded by self-produced extracellular matrix that holds them
together. These biofilms provide protection from antimicrobials, host defenses, and the
environment. They also exhibit slower diffusion of small molecules and limited bacterial growth
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due to constricted space and cause increased production of secondary metabolites including
antibiotics, pigments, and other small molecules (López et al. 2010).
B. subtilis also has potential anti-neuro-inflammatory properties. In a Caenorhabditis
elegans model of Parkinson’s Disease, various B. subtilis strains administered orally both
prevented and reversed toxic 𝛼-synuclein aggregation, while extending the lifespan. The gene
tasA, used to create extracellular matrix protein fibers necessary for biofilm formation, was
deemed important to the neuroprotective mechanism of B. subtilis. Dead B. subtilis and B.
subtilis extracts were also effective in protecting against 𝛼-synuclein aggregation, suggesting a
metabolite of the bacterium is responsible for its effects. Interestingly, B. subtilis also changes
gene expression in the sphingolipid metabolism pathway in the host, including upregulation of
lagr-1 (ortholog of ceramide synthase 1) and asm-3 (ortholog of acid sphingomyelinase, which
forms ceramide from sphingomyelin) and downregulation of sptl-3 (ortholog of serine
palmitoyltransferase, which is involved in the rate-limiting step of de novo ceramide synthesis).
Loss of function of lagr-1 or asm-3 in worms fed with B. subtilis increases 𝛼-synuclein
aggregation, while knockout of sptl-3 lowers aggregates (Goya et al. 2020).
RsbX phosphatase (PDB ID 3W40) is a PP2C subfamily member. It is involved in the
general stress response of B. subtilis, which is a signaling cascade that allows the bacterium to
respond to stressors from the environment and involves the formation of a large protein complex
called the stressosome that becomes phosphorylated during exposure to stress. The role of RsbX
phosphatase is to dephosphorylate the stressosome to stop the general stress response (Teh et al.
2015). It has specificity for phosphorylated RsbS, and negatively regulates 𝜎B to block the
transcription of stress-response genes (Yang et al. 1996). Specifically, it dephosphorylates Ser59
of RsbS and Thr205 of RsbR. (Teh et al. 2015, Vijay et al. 2000). The crystal structure for RsbX
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(PDB ID 3W40) contains an 𝛼𝛽𝛽𝛼 sandwich of two antiparallel 𝛽-sheets surrounded by 𝛼helices, with the catalytic center binding a Mn2+ ion (Teh et al. 2015). 3D structure alignment of
RsbX and human PP2C using UCSF Chimera reveals that these two proteins have very similar
3D structures, especially in the central 𝛽-sandwich and metal ion coordination sites (See
Appendix Figure A3 for image of structure match). Asp60, Gly61, Thr128, Asp239, Gly240, and
Asp282 are important for the coordination of the metal cation in the active site human PP2C
(Das et al. 1996) and are also found in alignment in RsbX as seen in the sequence alignment
made using the structure match (See Appendix Figure A4 for sequence alignment).
Expression and purification of human proteins can be difficult. When proteins from
humans are expressed in bacteria, they are expressed in lower levels, and may degrade during
purification. They also may contain domains that are toxic to the bacteria. Prokaryotes cannot
post-translationally modify the proteins, potentially making the protein structurally different and
less stable (Braun et al. 2002). As high levels of PP2C have demonstrated apoptotic effects
(Schwarz et al. 2006, Ofek et al. 2003), this protein may also potentially trigger cell death in the
host cell if it is purposely overexpressed in bacterial systems. Therefore, utilization of RsbX as a
model of human PP2C is advantageous for this study. It was hypothesized that ursolic acid
would cause changes to RsbX secondary structure that were indicative of unfolding toward a
random coil.

3.3. Materials & Methods
3.3.1. Expression of RsbX
To express RsbX (PDB ID 3W40), first Escherichia coli BL-21(DE3) cells were transformed
with RsbX_3W40_pET-28a (+)-TE plasmid with a 6-His tag and a TEV cleavage site. Plasmids
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were obtained from GenScript in lyophilized form and included antibiotic resistance to
kanamycin (see Table 2.1 for protein sequence). After transformation, Luria-Bertani (LB) agar
supplemented with 50 μg/mL kanamycin plates were inoculated with 85 μL each of the
transformant, quadrant streaked, and grown overnight at 37 °C to select for colonies that were
successfully transformed. Colonies were collected with a micropipette tip and dropped into 30
mL of LB medium with 50 μg/mL kanamycin for preculture growth at 225 rpm and 37 °C
overnight. Then, 4 mL of preculture was added to each 1 L of LB medium with 50 μg/mL
kanamycin for the main growth, which was shaken at 225 rpm and 37 °C until the optical density
at 600 nm (OD600) reached approximately 0.7. Protein expression was then induced by adding 1
mM of isopropyl 𝛽-D-1-thiogalactopyranoside (IPTG) and shaking the cells at 225 rpm and 18
°C for 15 hours (Teh et al. 2015, Suganuma 2009). Finally, cultures were centrifuged at 7,700
XG for 30 minutes at 4 °C. Supernatant was discarded, and the pellets were stored at -80 °C (see
Appendix for detailed expression protocol).

Table 2.1. Sequences of His tagged RsbX and wild-type RsbX. Differences in sequence are
indicated in bold lettering.
Name
Amino Acid Sequence of Protein
Reference
Plasmid
HHHHHHSSGENLYFQGGMIQVEENEHI
This paper
RsbX_3W40_pET- QTLVYQLNKEGKSICGDSFFMKADDKELI
28a (+)-TE
CAVADGLGSGSLANESSAAIKDLVENYAS
EDVESIIERCNQAMKNKRGATASILKINFE
QRQFTYCSVGNVRFILHSPSGESFYPLPISG
YLSGKPQKYKTHTATYEKGSKFIIHTDGLN
VPDIRSHLKKGQSVEEISNSLKMYTTSRKD
DLTYILGQLS
Wild-Type RsbX
MIQVEENEHIQTLVYQLNKEGKSICGDSFF
“UniProt: the
MKADDKELICAVADGLGSGSLANESSAAI
universal protein
KDLVENYASEDVESIIERCNQAMKNKRGA
knowledgebase
TASILKINFEQRQFTYCSVGNVRFILHSPSG
in 2021”
ESFYPLPISGYLSGKPQKYKTHTATYEKGS
KFIIHTDGLNVPDIRSHLKKGQSVEEISNSL
KMYTTSRKDDLTYILGQLS
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3.3.2. Purification of RsbX
Purification of RsbX was performed using nickel affinity chromatography. First, cell pellets were
thawed on ice and resuspended in 5 mL of washing buffer (50 mM Tris-HCl, 0.2 M NaCl, 20
mM imidazole, pH 8.0), 50 𝜇L of HaltTM EDTA-free protease inhibitor (Thermo Scientific), and
5 𝜇L of Benzonase nuclease. Resuspended cells were lysed at 1500 psi using a French press four
times before being centrifuged at 27,200 XG for 30 minutes at 4 °C. The supernatant was filtered
with a 0.45 𝜇m and then a 0.22 𝜇m syringe filter. Fast Protein Liquid Chromatography (FPLC)
purification was performed using an ÄKTA Purifier 900 (GE Healthcare). First, the FPLC was
run with a HisTrap FF 1-mL column (Cytiva) with an increasing imidazole gradient using the
washing buffer and an elution buffer of 50 mM Tris-HCl, 0.2 M NaCl, 500 mM imidazole, pH
8.0 (representative chromatogram: Figure 3.4). The fractions of the protein peak were combined,
and buffer exchanged into 50 mM Tris-HCl, 0.2 M NaCl, pH 8.0 using Zeba Spin 5-mL
desalting columns (Thermo Scientific). A second purification round was then run using a
HisTrap HP 1-mL column (Cytiva), with the same washing and elution buffers (representative
chromatogram: Figure 3.5) (see Appendix for detailed purification protocol).
Purified RsbX was buffer exchanged into 50 mM Tris-HCl, 0.2 M NaCl, pH 8.0 and stored at 4
°C. Quality and concentration of the protein sample was analyzed using UV-Vis
spectrophotometry (representative spectrum: Figure 3.6). Purity was assessed using 12% SDSPAGE with Coomassie Brilliant Blue staining (representative gel: Figure 3.7). Protein identity
was confirmed via mass spectrometry by the Chu lab at UNH.
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Figure 3.4. Chromatogram of the HisTrap FF purification of RsbX. Colored lines represent
absorption at 280 nm in mAU (blue), percent elution buffer relative to washing buffer (green),
and conductivity in mS/cm (brown), while the red numbers along the X-axis represent the
fractions eluted into the collection tubes. The peak at fractions 29 and 30 represents the elution
of the His tagged RsbX which was collected, combined, and buffer exchanged for the second
round of purification. The peaks from fractions 1-9 contain proteins without His tags, protein
aggregates, and other cellular waste.
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Figure 3.5. Chromatogram of the HisTrap HP purification of RsbX. Colored lines represent
absorption at 280 nm in mAU (blue), percent elution buffer relative to washing buffer (green),
and conductivity in mS/cm (brown), while the red numbers along the X-axis represent the
fractions eluted into the collection tubes. Two distinct elution peaks (as seen here) or a slight
shoulder on the left side of the elution peak is a characteristic of the HisTrap HP purification of
this protein. Fraction 29 contains the impurities and some RsbX, while fractions 30 and 31
contains completely pure RsbX. Therefore, it is fractions 30 and 31 that are combined and buffer
exchanged for use in experiments. The peaks between fractions 1-8 contain proteins without His
tags, protein aggregates, and other cellular waste that was not effectively removed during the
HisTrap FF purification.
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Figure 3.6. UV-Vis spectrum of purified RsbX. After performing baseline correction, the
concentration of protein for this sample was determined to be 70.54 𝜇M.
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Figure 3.7. Representative gel to assess purity of RsbX. Column flow through contains nonHis tagged proteins in a wide range of sizes (lane 2, FF and lane 5, HP). After FF purification,
RsbX still contains some impurities (lane 3). These impurities are removed during HP
purification (lane 6: waste). The purified RsbX is found at approximately 24 kDa (lane 8). Some
lanes (4, 7, 10) intentionally left empty. Ladder standard (lanes 1 and 9) with size markers in kDa
was also utilized.
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3.3.3. Sample Preparation for Thermal Denaturation CD Study
To obtain thermal stability measurements that were as accurate as possible to the conditions
inside of B. subtilis, it was desired to create a buffer that had similar ion concentrations and pH
as the cell. According to research by other groups, the pH of B. subtilis cells lies between 7.0 to
7.5 (Pandey et al. 2016, van Beilen and Brul 2013, Martinez et al. 2012). Additionally, ion
concentrations for Na+, K+, Cl-, and Mg2+ were found to be approximately 122 ± 11 mM, 27 ± 10
mM, 106 ± 13 mM, and 2 mM, respectively (Szatmári et al. 2020). To mimic these conditions,
an initial CD buffer was designed with 25 mM KH2PO4, 120 mM NaF, 2 mM MgSO4, pH 7.3.
The pH was adjusted using H2SO4, and the buffer was filtered with a 0.22 𝜇m vacuum filter to
remove any particulates.
Unfortunately, RsbX buffer exchanged into this original CD buffer quickly aggregated
and thus was not suitable for measurement with CD. Therefore, optimization of buffer conditions
needed to be performed. As the literature of the original purification of this protein also included
a high salt concentration (0.2-0.5 M NaCl) in the buffers (Teh et al. 2015, Suganuma et al. 2009),
it was hypothesized that increasing the salt concentration in the CD buffer may allow for
increased protein stability. Hence, a new CD buffer was prepared with 25 mM KH2PO4, 250 mM
NaF, 2 mM MgSO4, pH 7.3. For a preliminary test of these buffer conditions, 200 𝜇L each of
freshly purified RsbX in its original buffer (50 mM Tris-HCl, 0.2 M NaCl, pH 8.0) was buffer
exchanged into the higher salt buffer (25 mM KH2PO4, 250 mM NaF, 2 mM MgSO4, pH 7.3) as
well as the original CD buffer (25 mM KH2PO4, 120 mM NaF, 2 mM MgSO4, pH 7.3) using
Zeba Spin 0.5 mL columns (Thermo Scientific). Next, the protein in these 3 buffer conditions
was left at room temperature for 24 hours before visual examination and UV-Vis
spectrophotometry. After sitting on the benchtop, RsbX in its original buffer had visual
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aggregates. All 3 samples had reduced in quality compared to the freshly purified sample, with
the higher salt CD buffer showing the least degradation/baseline elevation (Figure 3.8). Thus, the
buffer selected for CD was the 25 mM KH2PO4, 250 mM NaF, 2 mM MgSO4, pH 7.3 as it most
closely mimicked the cell conditions while protecting the protein from abnormal degradation and
aggregation.

Figure 3.8. UV-Vis spectra of RsbX in various buffers after 24 hours. RsbX stored at 4 °C
(blue) retained its quality over 24 hours. RsbX in its original buffer at room temperature (green)
quality reduced the most, while the RsbX in the lower salt CD buffer (purple) degraded slightly
less and the RsbX in the higher salt CD buffer (yellow) retained the most quality of the buffers at
room temperature for 24 hours.

3.3.4. Thermal Denaturation CD Spectroscopy
Before CD measurements, protein samples were buffer exchanged into the CD buffer (25 mM
KH2PO4, 250 mM NaF, 2 mM MgSO4, pH 7.3) using Zeba Spin 0.5 mL columns (Thermo
Scientific) and diluted to approximately 5 - 15 𝜇M in the same buffer for a final volume of at
least 350 𝜇L, with concentration depending on the amount of protein successfully purified. UVVis measurements (Jasco V-650) and an initial CD scan at 20 °C were taken to ensure quality of
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sample and to determine the accurate concentration of the protein. CD measurements were
acquired using a Jasco J-1500 CD spectrometer equipped with a Peltier temperature controller,
using the Temperature Interval Scan Measurement program. Samples were measured in a 1.0
mm quartz cuvette with stopper. Data was acquired from 6 °C to 90 °C in 2 °C increments, with
a 1-minute equilibration period and 2 CD measurements taken at each temperature. For baseline
spectra, CD spectra were collected with the same parameters, but in 5 °C increments (see
Appendix Table A1 for detailed parameter information). A similar experiment was also
performed with protein MtnX (PDB ID 2FEA) (see Appendix Figure A2).
Data analysis was performed using MATLAB (MathWorks), assuming the two-state
model for protein folding. Fitting to elliptic curve was performed at 222 nm and 204 nm using
the least squares fit to generate molar ellipticity plots. 222 nm is located at the negative peak
characteristic of α-helices (Greenfield 2006c) and is used for monitoring the secondary structure
content of α-helical proteins (Wei et al. 2014, Mendonça and Hache 2012) while molar ellipticity
at 204 nm may be used for proteins containing with less α-helices and more 𝛽-sheets as it falls
within the positive peak seen for this secondary structure (Nonoyama et al. 2008, Greenfield
2006c, Leland et al. 2000, Medrano et al. 1996). Fit at 204 nm was ultimately used for the final
∆G and ∆H calculations (see Equation 3.1) (Li-Blatter and Seelig 2019, Seelig and Schönfeld
2016, Greenfield 2004, 2006a, b).
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(A) ln (𝐾
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(𝑇 − 𝑇 )

B) ∆𝐺 = ∆𝐻 (1 − 𝑇 )

𝑚
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Equation 3.1. The formulas used for calculation of ∆G and ∆H from CD measurements.
(A) Van’t Hoff equation derivative used in the MATLAB program to plot ln(K) versus 1/T to
subsequently calculate ∆H, which is defined by the slope of the resulting line. K, equilibrium
constant; T, any given temperature; Tm, melting temperature; ∆H, enthalpy change, R, gas
constant 8.3145 J ∙ mol-1 ∙ K. (B) Modified Gibbs free energy equation used to find the Gibbs
free energy of folding (∆G) at the selected temperature T (298 K).
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3.3.5. Study of Effects of Ursolic Acid on RsbX Folding
Immediately before CD experimentation, purified RsbX was buffer exchanged into the CD
buffer: 25 mM KH2PO4, 250 mM NaF, 2 mM MgSO4, pH 7.3 using a Zeba Spin 0.5 mL column
(Thermo Scientific). For each CD experiment, the RsbX was diluted to a concentration of 5.0
𝜇M in the same buffer. Ursolic acid was prepared by dissolving in ethanol and serial diluting to a
final concentration of 10.9 mM. A 10X dilution of the ursolic acid was then performed using the
CD buffer before use in the experiment. Ethanol solvent control was also diluted 10X in the CD
buffer and was volume-matched to the ursolic acid concentrations.
All CD measurements were acquired using a Jasco J-1500 CD spectrometer equipped
with a Peltier temperature controller. A 1.0 mm quartz cuvette with stopper was utilized. For
control measurements, the CD spectra of the CD buffer blank, RsbX in CD buffer alone, and
RsbX with ethanol diluted and volume-matched to the ursolic acid were taken in triplicate at 20
°C. (see Appendix Table A2 for detailed CD parameters). To test the effects of ursolic acid on
RsbX folding, RsbX was combined with 1:1, 1:2, 1:3, or 1:10 concentrations of ursolic acid into
a final volume of 350 𝜇L in CD buffer. The sample was incubated at room temperature for 5
minutes to enable time for potential structural changes, then immediately transferred into the CD
cuvette and CD spectra were taken in triplicate at 20 °C (see Appendix Table A2 for detailed CD
parameters). Baselines were corrected using CD measurements of the buffer with ethanol or
ursolic acid alone. The experiment was completed in triplicate. Experimental protocols were
adapted from Ding et al. (2018) and Peng et al. (2014).
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3.4. Results
3.4.1. Thermodynamics of RsbX
The CD measurements of the thermal denaturation of RsbX in 25 mM KH 2PO4, 250 mM NaF, 2
mM MgSO4, pH 7.3 resulted in a curve with an isodichroic point characteristic of the two-state
model (Figure 3.9A). As temperature increased, the negative peak decreased in intensity (became
more positive) downward while the positive peak also decreased in intensity (became less
positive) (Figure 3.9A). This indicates an overall unfolding of the protein secondary structure
and progression toward a random coil through a decrease in 𝛼-helical and 𝛽-sheet content.
Spectra measurements of the buffer blank did not display any protein contents (Figure 3.9A) and
this data was subtracted from the sample data for the elliptical fitting analyses. Data was
compared at 222 nm versus 204 nm (Figure 3.9B) and 204 nm was selected as better wavelength
for fitting due to an increased ellipticity of data at this wavelength; data at 204 nm was utilized
for the final analysis (Figure 3.9C). Importantly, for this analysis, the data at temperatures higher
than 80 °C were excluded from the calculation due to excessive protein aggregation (Figure
3.10). The MATLAB calculations (see Equation 3.1) were performed both with subtraction of
the buffer blank, and experiment was repeated in triplicate (Table 3.1). The final average values
of the triplicate results with buffer blank subtracted were a Tm of 321.5 K, ∆Hm of 6.67 x 104
cal/mol, and ∆G of 4.88 x 103 cal/mol.

Table 3.1. Thermodynamic values for RsbX. Calculations were performed using MATLAB
and fitting of data to an elliptical curve at 204 nm.
∆Hm (cal/mol)
6.79 x 104
6.55 x 104
6.68 x 104

∆G (cal/mol)
5.16 x 103
4.72 x 103
4.75 x 103

Tm (K)
322.5
321.2
320.8
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(A)

(B)
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Figure 3.9. Representative CD spectroscopy results for RsbX. (A) Thermal denaturation CD
spectra of RsbX compared with the buffer blank (black dashed line). (B) Data with buffer
subtracted and fit to elliptical curve at 222 nm (red) and 204 nm (blue). (C) Elliptical curve
fitting graph at 204 nm.
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(A)

(B)

(C)

(D)

(E)

Figure 3.10. Aggregation of RsbX during thermal denaturation experiment. Aggregation
progressed throughout the temperature interval measurements, with no aggregates at the
experiment start at 6 °C (A) until 58 °C (B). At 64 °C (C) small aggregates are present, which
become larger as the experiment progresses to 68 °C (D). By the end of the experiment at 90 °C
(E), the aggregates are large, and many have sedimented to the bottom of the cuvette.

3.4.2. Ursolic Acid Effects on RsbX Secondary Structure
There were no significant visual differences between the effects of UA and ethanol on the CD
spectrum of RsbX at a treatment concentration equal to that of the protein (Figure 3.11). Results
were similar when the treatments were added at 2:1, 3:1, and 10:1 ratios of treatment: RsbX (See
Appendix Figure A5). Both UA and ethanol caused a similar increase in intensity of the negative
CD peak at approximately 218 nm. They did not cause any overall changes in the positive CD
peak at approximately 196 nm, except for a slight increase in its intensity at 5 𝜇M
concentrations. It is known that α-helices have a positive peak at 193 nm and negative peaks at

82

222 and 208 nm. Meanwhile, β-sheets typically have a positive peak at around 198 nm and
negative peak at 215 nm (Wei et al.2014, Greenfield 2006c). Therefore, the observed solventinduced changes in the RsbX spectra are suggestive of a slight increase in β-sheet content. This
was confirmed by the secondary structure analysis performed using BeStSel (Micsonai et al.
2018) (Table 3.2).

Figure 3.11. CD results of RsbX treated with ursolic acid or ethanol. The effects of UA in
ethanol (blue) and ethanol (red) at on an equimolar concentration of RsbX are observed. Native
RsbX (black) was also measured.
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Table 3.2. Secondary structure approximations of RsbX with various treatments.
Treatment

α-helix (%)

𝛽-sheet (%)

β-turn (%)

Other (%)

None
15 𝜇M UA
15 𝜇M EtOH

15.3
17.8
19

30.5
33.7
36.9

12.2
11.7
11.6

42
36.8
32.5

3.5. Discussion
In this study, expression and purification protocols were developed for the B. subtilis protein
RsbX, as well as methods for the CD study of thermal stability for proteins from this bacterium.
To ensure biological accuracy, a buffer for CD was designed that closely mirrored the pH and
ion concentrations found inside B. subtilis. However, the purified protein was unstable and could
not be studied in this initial CD buffer due to aggregation. To circumvent this problem, the buffer
was replicated with a higher salt concentration, and the proteins were stable and able to be
successfully studied in this buffer. Sodium chloride is a cost-effective and highly available salt
option. However, chloride ions have a strong absorbance at wavelengths under 200 nm, which
could change the observed CD spectra by increasing the low wavelength cutoff, and lead to
additional noise. Meanwhile, fluoride ions have a much lower absorbance in the far UV range
and do not interfere with the spectra (Miles and Wallace 2016), therefore F- was selected for use
in the CD buffer. The Hofmeister series of salts lists anions from most to least effective at
driving protein folding among other effects, with SO42- being the most effective, followed by Fand Cl- (Hani et al. 2019, Pegram et al. 2010). The strong Hofmeister salts stabilize proteins by
strengthening the hydrophobic effect using their smaller cations and larger anions (Hani et al.
2019). Several studies have demonstrated the ability of these salts to increase protein stability
both in vitro and inside bacterial cells (Hani et al. 2019, Maity et al. 2018, Pegram et al. 2010,
Tadeo et al. 2009). Thus, the optimized high salt CD buffer is ideal for the study of Bacillus

84

subtilis proteins as it mostly mimics cellular conditions while retaining a salt concentration that
stabilizes the proteins to ensure all unfolding is due to the increasing temperature during the CD
experiment, and not from the buffer itself.
During the purification process, two elution peaks were seen when performing the second
round of purification using the HisTrap HP column. The purified protein eluted in the second
peak, while the first peak contained some RsbX along with contaminants of different molecular
weights than RsbX. This likely occurred because there are many native proteins in E. coli BL21(DE3) which have clusters of histidine residues or metal binding sites and therefore also
display affinity for nickel ions (Robichon et al. 2011). Although this issue was averted by
collecting the two peaks separately and performing SDS-PAGE analysis, other methods may be
utilized to avoid the contaminants from eluting near the tagged protein. Optimization of the
imidazole concentrations in the sample, wash, and elution buffers is one effective method to
prevent co-elution of contaminants, as these host proteins typically have lower affinity for nickel
than the designed His tag (Haneskog 2006). The E. coli strain itself could also be engineered to
express the contaminants with a mutation to reduce their metal affinity, or to have the native
proteins contain an alternative affinity tag to perform an additional round of chromatography
(Robichon et al. 2011).
The thermodynamic values of RsbX calculated from the thermal denaturation CD studies
were a Tm of 321.5 K, ∆Hm of 6.67 x 104 cal/mol, and ∆G of 4.88 x 103 cal/mol. The Tm of this
protein is consistent with the optimum temperature for B. subtilis growth being 30-37 °C with a
maximum temperature of 43 °C and minimum of 18 °C (Cook 1996), as these temperatures
would enable RsbX to maintain its native state. ∆G is temperature-dependent, with a positive ∆G
at a given temperature meaning the native state is favored (Rees and Robertson 2001). Thus, a
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∆G of 4.88 x 103 cal/mol at 273 K (0 °C) suggests that the native state of RsbX is highly favored
at this temperature. A higher ∆H value indicates an increase in molecular energy states and
broken bonds; it tends to increase with an increasing temperature (Cooper 1999). The enthalpy
value at the melting temperature, ∆Hm, for RsbX was found to be 6.57 x 104 cal/mol, thus
suggesting at this melting temperature the protein is breaking down.
Ursolic acid did not significantly impact the secondary structure of RsbX as studied by
CD spectroscopy. Ethanol solvent alone changed the folding in a very similar manner to the
same concentrations of UA, indicating that the effects observed were simply from the solvent.
Ethanol has been observed to impact protein secondary structure in various CD studies, including
causing an increase in 𝛼-helix and 𝛽-sheet content for several human proteins (Jirgensons 1978)
and denaturing bovine serum albumin (BSA) (Liu et al. 2010). It also is known that UA acid can
affect the CD spectra of proteins. Other researchers have found that UA and oleanolic acid are
able to induce conformational changes in bovine serum albumin as seen by changes in CD
spectroscopy (Peng et al. 2014). UA and oleanolic acid also compact the structure and decrease
the stability of 𝛼-glucosidase by increasing 𝛼-helix and random coil content and decreasing 𝛽sheet content as monitored by CD (Ding et al. 2018). Notably, ethanol is achiral and UA does not
absorb in the region that was tested, therefore the changes in spectra observed are not due to the
mere presence of these molecules. Because of the similar results achieved between UA and
ethanol solvent, it is concluded that UA likely does not significantly impact the folding of RsbX.
Although ursolic acid is much more soluble in DMSO than in ethanol, ethanol solvent
was utilized for this experiment because even low concentrations (5% v/v) of DMSO alone were
found to cause strong protein denaturation and large perturbations in the CD spectrum. The
ethanol solvent-induced changes in the CD spectra of RsbX indicated a slight increase in β-sheet
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content. The catalytic domain of RsbX and human PP2C consists of central antiparallel 𝛽-sheets
surrounded by 𝛼-helices (Teh et al. 2015, Das et al. 1996, Barford et al. 1998). Therefore, it is
possible that the ethanol solvent of UA may be stabilizing the catalytic domain of RsbX. To
confirm that UA does not significantly affect this protein, activity assays may be performed in
future research, such as those implemented by Perry et al. (2012). These assays would also allow
for the determination of if the changes in folding of RsbX induced by the ethanol solvent in this
experiment are affecting the activity of this enzyme. In this experiment, binding of ursolic acid to
RsbX was not assessed. Therefore, it is unknown whether this molecule is truly interacting with
this protein. Experiments assessing protein-ligand interaction may be implemented in future
research.
RsbX was used as a model of PP2C, due to better feasibility of expression and
purification of this model bacterial protein using the available resources of this laboratory.
However, human PP2C has previously been recombinantly expressed in E. coli and purified
using nickel affinity chromatography by a different research group (Travis et al. 1997). As
bacteria cannot post-translationally modify proteins (Braun et al. 2002), it is likely that posttranslational modifications are not necessary for the stable folding of human PP2C, enabling
recombinant expression of this protein in bacterial cells. Rat PP2C has also been successfully
recombinantly expressed in eukaryotic HEK293 cells (Tong et al. 1998). The successful
recombinant production of PP2C by these other groups indicates the potential for future research
performing this experiment using the human PP2C rather than its bacterial counterpart.
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CHAPTER 4
CONCLUSIONS & FUTURE DIRECTIONS

4.1. Conclusions
Aim 1: Investigate the effects of ursolic acid on lipid raft formation in neuronal cells.
Working hypothesis: ursolic acid prevents or reduces the formation of lipid rafts. In this regard,
it was found that prophylactic treatment with UA reduced the lipid raft content of SH-SY5Y
cells during neuro-inflammation simulated with TNF𝛼 and restored the membrane dynamics to
those like the control state. Meanwhile, in SH-SY5Y cells without TNF𝛼, UA changed the
membrane dynamics in a different manner, potentially causing lipid raft microdomains to
become more spread out when compared to vehicle control. It appears that UA may possesses an
ability to antagonize the effects of TNF𝛼 on lipid rafts in neuronal cells. Overall, it is concluded
that UA alters lipid raft dynamics in neuronal cells, with differential effects in inflamed versus
non-inflamed cells.

Aim 2: Study the impact of ursolic acid on protein folding of a serine phosphatase. Working
hypothesis: ursolic acid disrupts the folding of RsbX, a bacterial serine phosphatase used to
represent the similar human protein phosphatase PP2C. In this regard, 6-His tagged RsbX was
successfully recombinantly expressed in the BL-21(DE3) strain of E. coli using the designed
expression protocol including kanamycin resistance and induction with isopropyl 𝛽-D-1thiogalactopyranoside (IPTG). Nickel affinity chromatography with a HisTrap FF column alone
removed many contaminants, but for the protein to become completely pure, the HisTrap FF
purification needed to be followed by a subsequent HisTrap HP purification. RsbX was stable at
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4 °C in its washing buffer with imidazole removed, and a buffer for CD studies was successfully
designed that mostly mimicked cellular conditions but with an elevated concentration of salt to
stabilize the proteins. CD thermal denaturation experiments revealed an average Tm of 321.5 K,
∆Hm of 6.67 x 104 cal/mol, and ∆G of 4.88 x 103 cal/mol for this protein. In subsequent CD
studies of ursolic acid or solvent control with the native RsbX, it was found that ursolic acid does
not significantly impact the folding of RsbX. Although UA did slightly change the secondary
structure of RsbX, the same concentrations of ethanol solvent control modified the structure in
an extremely similar manner, suggesting it was the solvent that caused the effects and not the
UA. The working hypothesis is rejected.

4.2. Future Directions
This research focused on the fundamental biochemistry and potential mechanisms of action for
UA a naturally occurring triterpenoid with anti-inflammatory potential. There are many other
potential future directions to assess UA as a prospective therapeutic for neuro-inflammation.
Additional studies should first be focused on in vitro research. An ELISA experiment could be
performed to evaluate the impact of UA on NOX2 assembly. This would allow for the evaluation
of if the observed effects of UA on lipid membrane dynamics modulate NOX2 assembly which
occurs on lipid rafts. Cells would be treated with UA +/- TNF𝛼, then fractionated into membrane
versus cytosolic components and screened for the presence of cytosolic components of NOX2
(p40phox, p47phox, p67phox) in the membrane versus cytosol. If the majority of these NOX2
components were found at the membrane, it would indicate that NOX2 is assembling, while
more in the cytosol would suggest that assembly was being inhibited. Additionally, assays to
measure overall inflammation and cytokine levels could be utilized to assess whether UA can
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reduce the overall level of neuro-inflammation in specific cell types, using methods such as the
Meso Scale Discovery (MSD) assay.
Additional investigation around lipid raft dynamics would be helpful to enhance the
understanding of the impact of UA on these domains. It appears that UA alone causes a unique
effect on the membrane dynamics of SH-SY5Y cells, which differs from its impact on inflamed
cells. It would be beneficial to study this interaction further, to ensure the effect on normal cells
is not damaging normal physiological signaling, and to investigate if this is at all a potentially
neuroprotective or prophylactic effect. One prospective method would be to isolate the lipid rafts
of treated cells and to perform lipidomic studies of these domains via mass spectrometry. The
levels of downstream effectors of both pathologic and normal physiologic signaling pathways
associated with lipid rafts could also be compared in treated versus untreated cells, using
techniques such as Western Blot or ELISA.
More research on the effects of UA on protein folding would also be helpful to uncover
the exact way in which it exerts its anti-neuro-inflammatory effects. The protein folding studies
performed here could be repeated with other surrogate proteins, or with human proteins such as
human PP2C, PP2A, TNF𝛼, or amyloid 𝛽. The techniques used in this experiment for the
thermodynamic study of proteins may also be utilized to examine the ∆Go of folding for known
neuro-inflammatory proteins or peptides such as tumor necrosis factor 𝛼 and amyloid 𝛽, to
characterize their stability. Additionally, from this experiment, it is unable to be concluded
whether ursolic acid is binding to RsbX. To assess binding, additional experiments may be
carried out such as nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), or
isothermal titration calorimetry (ITC), techniques which enable the study of protein-ligand
interactions.

90

If UA proves to be effective at preventing neuro-inflammation during further in vitro
research and a potential mechanism of action (MOA) is found, this compound may be eventually
advanced to in vivo testing. In addition to confirmation of any proposed MOA, in vivo research
would enable the determination of whether UA molecules can cross the BBB, and the
comparison of potential routes of administration for UA (i.e., oral, intravenous injection,
intrathecal injection, or intracerebroventricular injection). This in vivo research could also allow
for the determination of the pharmacologic potency of this potential drug. It is hoped that the
research performed on UA, including that outlined in this thesis as well as future work in this
area, will someday lead to the development of an approved UA-based therapeutic that can be
delivered to patients suffering from neurodegenerative diseases.
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APPENDIX
RsbX Expression and Purification Protocol
RsbX Expression
1. Thaw E. coli BL-21(DE3) competent cells on ice for 20 minutes.
2. Combine 30 𝜇L of BL-21(DE3) cells with 600 ng of RsbX_3W40_pET-28a (+)-TE
plasmid (GenScript), mix very gently by lightly tapping the side of the tube, and incubate
for 35 minutes on ice.
3. Heat shock cells at 42 °C for 40 seconds, then immediately put the cells on ice for 2
minutes and 30 seconds.
4. Add 240 𝜇L of S.O.C. medium to the cells.
5. Incubate the cells in an orbital shaker at 37 °C and 225 rpm for 1 hour.
6. Inoculate 3 Luria-Bertani (LB) agar plates containing 50 𝜇g/mL kanamycin with 85 𝜇L
each of the transformed cells, and streak using a quadrant streak.
7. Seal plates with Parafilm and incubate overnight, agar side up, at 37 °C for approximately
15 hours. Store plates at 4 °C until use of colonies. Plates can be stored for up to 14 days.
8. Scrape single, isolated bacterial colonies from the agar using a P200 pipet tip and drop
them into approximately 30 mL of liquid LB medium supplemented with 50 𝜇g/mL
kanamycin.
a. A total of 100 mL of LB should be prepared for this step. Use 90 mL for the preculture growth and save the remaining 10 mL for blanking the UV-Vis
spectrophotometer during the main growth.
9. Incubate the pre-cultures in an orbital shaker at 37 °C and 225 rpm overnight for
approximately 15 hours.
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10. Transfer 4 mL of the most turbid pre-culture into each 1 L of liquid LB supplemented
with 50 𝜇g/mL kanamycin for the main growth.
a. It is recommended to use 5 L of LB total, in 5 separate flasks.
b. If desired, freezer stocks can be prepared by combining 750 𝜇L of the successful
pre-culture with 750 𝜇L of 50% v/v glycerol in milliQ-H2O into a cryovial, snap
freezing in liquid nitrogen, and then storing at -80 °C. Then, instead of
transforming the bacteria again for future growths, one can skip to step 6 of the
expression protocol and scrape the surface of the stock for plate inoculation.
11. Incubate the main growths in an orbital shaker at 37 °C and 225 rpm until the optical
density at 600 nm (OD600) read using a UV-Vis spectrophotometer reaches 0.7.
a. It will take approximately 4 hours to reach this OD600. It is recommended to
monitor the OD600 every half hour to hour, beginning at 2 hours after starting the
main growth.
b. Store flasks that reach an OD600 of 0.7 at 4 °C until all flasks have achieved this
OD600 value.
12. Induce recombinant protein expression by adding 1 mM of isopropyl 𝛽-D-1thiogalactopyranoside (IPTG).
13. Allow induced cells to grow at 18 °C and 225 rpm for 15 hours.
14. Centrifuge cells at 7,700 XG and 4 °C for 30 minutes.
a. It is recommended to use 4 centrifuge bottles total. This step will need to be
repeated multiple times to use all of the culture. In between centrifugations,
discard the supernatant, and the store cultures at 4 °C.
15. Discard supernatant and store cell pellets at -80 °C.
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RsbX Purification
1. Thaw a cell pellet on ice for 20 minutes.
2. Resuspend cell pellets in 5 mL of washing buffer (50 mM Tris-HCl, 0.2 M NaCl, 20 mM
imidazole, pH 8.0) with 50 𝜇L of HaltTM EDTA-free protease inhibitor (Thermo
Scientific) and 5 𝜇L of Benzonase nuclease.
3. Lyse cells using a French press at 1500 psi four times.
4. Centrifuge lysate at 27,200 XG and 4 °C for 40 minutes.
5. Syringe filter the supernatant with a 0.45-𝜇m filter and then a 0.22-𝜇m filter.
6. Purify the filtered supernatant using Ni-affinity chromatography with a Fast Protein
Liquid Chromatography instrument (FPLC; GE Healthcare ÄKTA Purifier 900) equipped
with a HisTrap FF 1-mL column (Cytiva). Elute the RsbX protein using an increasing
imidazole concentration gradient up to 500 mM.
a. Washing buffer: 50 mM Tris-HCl, 0.2 M NaCl, 20 mM imidazole, pH 8.0.
b. Elution buffer: 50 mM Tris-HCl, 0.2 M NaCl, 500 mM imidazole, pH 8.0.
7. Buffer exchange eluted protein fractions into 50 mM Tris-HCl, 0.2 M NaCl, pH 8.0 using
Zeba Spin 5-mL desalting columns (Thermo Scientific).
a. Save a 15 𝜇L aliquot for SDS-PAGE.
8. Purify the protein with another round of Ni-affinity chromatography using the same
buffers as previously used (See Step 6) but with a HisTrap HP 1-mL column (Cytiva).
a. It is likely that there will be 2 peaks. The first peak typically contains impurities
and some RsbX, while the second peak will contain the pure RsbX protein.
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9. Buffer exchange eluted protein fractions into 50 mM Tris-HCl, 0.2 M NaCl, pH 8.0 using
Zeba Spin 5-mL columns (Thermo Scientific). If there are multiple peaks, buffer
exchange each peak separately using multiple columns.
10. Analyze the purity of the protein using 12% SDS-PAGE with Coomassie Brilliant Blue
stain. Assess the quality and concentration of the protein using UV-Vis
spectrophotometry.

Table A1. Temperature Interval Scan Measurement CD parameters.
Photometric mode
CD scale
FL scale
D.I.T.
Bandwidth
Measurement range
Data pitch
Scanning speed
Start mode
Scanning mode
Baseline correction
Shutter control
No. of accumulations
Start temp.
End temp.
Data Interval
Temp. gradient
Temp. ramp mode
Wait time
Start condition
End condition
Halt temperature ramping
during measurement
Control sensor
Monitor sensor

CD, HT
20 mdeg/0.05 dOD
200 mdeg/1.0 dOD
4 sec
8.00 nm
350-190 nm
0.2 nm
50 nm/min
Immediately
Continuous
No Correction
Shutter is open and closed automatically, and shutter is
closed between measurements.
2 times
6 °C
90 °C
2 °C (5 °C for buffer blank)
2 °C /min
Halt
60 sec
Keep within +/- 0.1 °C of the target temperature for 5
seconds.
Return to start temp.
Yes
Holder
Holder
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Figure A1. Additional confocal images of lipid raft-stained cells. (A) Untreated cells, (B)
cells treated with only ursolic acid, (C) Cells treated with solvent for TNF𝛼 (1X PBS with 0.1%
BSA), (D) cells treated with TNF𝛼, (E) cells treated with ursolic acid prior to TNF𝛼.

Figure A2. CD spectra for the thermal denaturation of B. subtilis protein MtnX (PDB ID:
2FEA). Protein spectra in various temperatures is shown in rainbow colors, and the buffer blank
(black dotted line) was subtracted from the data. Tm= 322.7 K, ∆Hm= 4.67 x 104 cal/mol, and
∆G= 3.58 x 103 cal/mol (n=1).
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Figure A3. 3D structure alignment of RsbX and PP2C. The B. subtilis protein RsbX (blue)
and the human protein PP2C (red) show strong tertiary structure homology, especially in the
central beta-sheet region where the beta-sheets are aligned both in position and directionality.
Sequence alignment score= 163.1, RMSD between 74 pruned atom pairs is 0.919 angstroms
(8.881 across all 195 pairs).
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Figure A4. Sequence alignment generated from the structural match of RsbX and PP2C.
RsbX (3w40) and PP2C (1a6q) have similarity in many key residues for phosphatase activity.
Table A2. Single-temperature measurement CD parameters.
Photometric mode
CD scale
FL scale
D.I.T.
Bandwidth
Measurement range
Data pitch
Scanning speed
Start mode
Scanning mode
Baseline correction
Shutter control
No. of cycles
Cycle interval
Start condition
End condition
Halt temperature ramping
during measurement
Control sensor
Monitor sensor

CD, HT
20 mdeg/0.05 dOD
200 mdeg/1.0 dOD
4 sec
8.00 nm
350-190 nm
0.2 nm
50 nm/min
Immediately
Continuous
No Correction
Shutter is opened and closed automatically.
3 times
0 sec
Keep within +/- 0.2 °C of the target temperature for 5 sec.
Return to start temp.
Yes
Holder
Holder
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Figure A5. CD spectra of RsbX with ursolic acid at varying concentrations and volume-matched
ethanol controls.
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145. Kułakowska, A., Żendzian-Piotrowska, M., Baranowski, M., Konończuk, T., Drozdowski,
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